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 Appropriate regulation of gene expression is important for the 
development and homeostasis of multicellular organisms. DNA sequence- 
specific transcription factors play a central role in regulating the first step of gene 
expression, transcription. The aberrant expression of transcription factors is a 
common mechanism for the initiation and progression of many human cancers. 
The ETS family of transcription factors consists of twenty-eight human proteins 
that contain a conserved DNA-binding domain, termed the ETS domain. ETS 
factors have varied roles in organismal development and disease etiology. For 
example, ETS proteins from the ERG and ETV1/4/5 subfamilies are 
overexpressed in the majority of prostate cancers and contribute to cancer 
initiation and progression. In stark contrast, EHF and SPDEF are two ETS factors 
present in normal prostate tissue that have been characterized as tumor 
suppressors whose genes are often deleted during cancer progression. The 
phenotypic dichotomy displayed between these subclasses of ETS factors 
suggests that the understanding of the molecular mechanisms that underlie 
transcription factors’ roles in normal and disease settings may provide additional 
opportunities for therapeutic intervention.  
 Here we describe the DNA-binding autoinhibition of ETS factors ETV1, 
 
iv 
ETV4, and ETV5. An intrinsically disordered region and an α-helix cooperate to 
inhibit DNA-binding by altering the positioning of the DNA-recognition α-helix of 
the ETS domain. These inhibitory elements are distinct from those that have 
been previously described for other ETS factors. We also characterize the 
interaction of Mediator subunit 25 (MED25) with the transcriptional activation and 
DNA-binding domains of ETV4. The inhibitory α-helix of ETV4 provides a unique 
interaction surface for MED25, as compared to other ETS domains, and 
interaction with MED25 activates the DNA-binding of ETV4. We also 
demonstrate the differential ability of ETS factors to bind to DNA with JUN-FOS 
at composite DNA binding sites. These distinct intra- and intermolecular 
interactions distinguish ETS oncoproteins and tumor suppressors in prostate 
cancer and may, in part, underlie their phenotypic differences. Finally, we present 
an assay for ETS-DNA interactions that is amenable to high-throughput 
screening for small molecule inhibitors. This assay could be further modified to 
incorporate any of the previously described partnerships.
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Gene-specific regulation of transcription  
Appropriate spatiotemporal control of gene expression is necessary for 
normal development and homeostasis1. Conversely, misregulation of key genes 
is causal for many diseases, including cancer2. Transcription is the first step of 
gene expression and is a highly coordinated process. DNA sequence-specific 
transcription factors bind to cognate sites in DNA and modulate the recruitment 
of RNA polymerase II (Pol II), general transcription factors (GTFs), the Mediator 
complex, chromatin-modifying or –remodeling complexes, and other transcription 
factors. A network of molecular interactions dictates the unique composition of 
proteins at any given gene, and this diverse composition is integrated into a 
graded ability to recruit and activate Pol II for processive transcription3,4 (Fig. 
1.1a).  
 Typical DNA sequence-specific transcription factors have a discrete DNA-
binding domain (DBD) that recognizes related DNA binding sites with varying 
affinty5, and an activation domain(s) (AD) that interacts with transcriptional 
coactivators2,6. DBDs have diverse structural composition, such as 
homeodomains, zinc fingers, helix-loop-helix, or basic region leucine zippers, and 
read both specific DNA sequences and the general shape of DNA through 
contact with the exposed base on a nucleotide or the phosphate backbone of 
DNA, respectively7. Multiple transcription factors can coordinately control the 
transcription of specific genes by modifying protein-DNA contacts and/or by 
adding new protein-protein contacts8-15. The largest structurally characterized 
example is that of the IFN-B enhancer9,10 (Fig. 1.1c). Seven distinct transcription 
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factors bind to a ~ 50 nucleotide segment of DNA. Interestingly, despite the 
dense binding of transcription factors on the IFN-B enhancer, there is a paucity of 
protein-protein interactions between the factors. Additionally, mutagenesis of the 
protein contacts demonstrates that they are not required for cooperative DNA-
binding in this example. Rather, this suggests that the cooperative binding of 
multiple transcription factors at the IFN-B enhancer is facilitated through DNA. 
Other examples have more explicitly demonstrated the role of DNA sequences in 
influencing cooperative protein binding16, as well as protein conformation and 
regulatory activity17. Thus, both the DNA sequences of transcription factor 
binding sites and the spacing between these binding sites influence the binding 
of multiple transcription factors at regulatory regions.  
 Sequence-specific transcription factors utilize an AD(s) to interact with 
GTFs and transcriptional coactivators, such as subunits of the Mediator complex, 
to recruit and activate Pol II.  ADs are disordered in isolation but often become 
more α-helical in the presence of a coactivator target18-22. ADs can interact with 
multiple distinct coactivators23-27, and the disordered nature of ADs is postulated 
to be important for this promiscuous recognition28. For example, p53 AD - 
coactivator structures demonstrate that the specific coactivator target influences 
the coactivator-bound structure of the AD29-33 (Fig. 1.1d). Furthermore, distinct 
p53 AD mutants differentially affect gene-specific transcription34, which suggests 
that there is variable requirement for individual p53 – coactivator interactions at 
particular p53 target genes. In sum, the transcription factors at a regulatory 
region affect the binding of other transcription factors and recruit of transcriptional 
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coactivators and GTFs to influence transcriptional output from nearby genes.  
 
ETS transcription factors 
The ETS family of transcription factors consists of 28 genes in humans, 
defined by the obligate presence of the ETS domain, a winged helix-turn-helix 
DNA-binding domain35 (Fig. 1.2). The ETS domain is conserved across human 
ETS factors; ~ 15% and 45% of sequences are absolutely or functionally 
conserved, respectively. This conservation is more striking from a structural 
standpoint as the structures of ETS domains from different factors align with 
typical root-mean-square-deviation values of ~ 1 Å36. A subset of ETS factors 
also contain a pointed (PNT) domain which facilitates protein-protein 
interactions35. Diverse sequences and structures that flank the ETS domain in 
different ETS factors contribute to autoinhibition (discussed below) and/or 
facilitate protein-protein interactions35,37. Outside of these structured domains, 
ETS factors primarily consist of intrinsically disordered regions (IDRs), which are 
enriched in transcription factors in general38,39. 
 Sequences that reside outside of the ETS domain and inhibit the DNA-
binding of the ETS domain have been observed in most ETS subfamilies40-46 and 
have been structurally described for ETS147,48, ETV637,49,50, and ERG51 (Fig. 
1.3). In ETS1, the most thoroughly characterized example of DNA-binding 
autoinhibition in the ETS family, four α-helices that flank the ETS domain impart 
a slight ~ 2-fold level of inhibition52,53. An IDR, termed the serine-rich region 
(SRR), increases this inhibition to ~ 30-fold and phosphorylation of serines within 
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the SRR further increases inhibition another ~1000-fold47,48. Cooperative DNA-
binding with either PAX5 or RUNX1 ablates the autoinhibition of ETS1 by 
disrupting the inhibitory module13-15,54. Therefore, ETS1 autoinhibition serves as a 
model for the integration of posttranslational modifications and protein-protein 
interactions in the regulation of DNA-binding affinity. This regulation provides a 
route for transcriptional regulation by an individual ETS factor, as discussed 
below. ETV6 and ERG, the other two ETS factors for which autoinhibition has 
been structurally characterized, have distinct mechanisms of autoinhibition, 
implying that the cellular regulation of autoinhibition for these factors will also be 
distinct.   
Some ETS factors have been described as master regulators of cell 
identity. For example, SPI1, also known as PU.1, dictates differentiation of 
hematopoietic progenitors along the myeloid lineage55, and ETV2 is sufficient for 
the conversion of fibroblasts into endothelial cells56. Most cell-types express 
multiple ETS factors and conversely, most ETS factors are expressed in multiple 
cell-types57. This co-expression of ETS factors results in many ETS DNA-binding 
sites in the genome being redundantly occupied by multiple ETS proteins58. 
However, the broad array of phenotypes produced from genetic disruptions of 
individual ETS factors35, as well as the examples of ETS factors serving as 
master regulators of cell identity, suggest that some genes are regulated by a 
single ETS factor.  
The determinants of redundant regulation by multiple ETS factors versus 
specific regulation by an individual ETS factor have been described for ETS1 in 
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T-cells. Whereas redundantly regulated sites contain near-consensus ETS-
binding DNA sequences, ETS1-specific sites possess variant DNA sequences 
that disproportionately weaken the binding of other ETS factors such as ELF159. 
Additionally, only ETS1-specific sites are part of an ETS-RUNX composite DNA-
binding site58,59. RUNX1 and ETS1 cooperatively bind to DNA by relieving the 
autoinhibition of the other factor54,58,60. In summary, variant ETS sites and 
cooperative binding with other transcription factors establish the specific 
regulation of genomic sites by individual ETS factors.  
 
Phenotypic diversity of ETS factors in prostate cancer 
ETS transcription factors exhibit an intriguing phenotypic dichotomy in the 
context of prostate cancer. EHF and SPDEF, two ETS factors that are highly 
expressed in normal prostate57, are commonly down-regulated or deleted during 
disease progression61-67. These ETS proteins are of prognostic value in prostate 
cancer as patients with lower levels display poorer overall and biochemical 
recurrence-free survival61,63, and patients with higher levels of SPDEF have 
prolonged response to androgen deprivation therapy67. In contrast, ETS factors 
from the ERG and ETV1/4/5 subfamilies are overexpressed in the majority of 
prostate cancer patients68. Chromosomal rearrangements resulting in prostate-
specific or constitutively-expressed promoters controlling the transcription of 
ERG or ETV1/4/5 genes are the most common cause for the overexpression of 
these genes53,68-70, although other cellular mechanisms have been described71. 
ERG or ETV1/4/5 factors are sufficient to generate prostatic intraepithelial 
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neoplasia, an early stage of prostate cancer72-74. Additional genetic events, such 
as the deletion of PTEN, are frequently observed in prostate cancer patients with 
ERG or ETV1/4/5 rearrangements68,75, and these multiple genetic events 
synergize to generate prostate cancer in mouse models72,73,76-78. Interestingly, 
ETV1 and ETV4 mouse models exhibit more aggressive and metastatic forms of 
disease as compared to ERG mouse models, although it is debated as to 
whether this difference faithfully reflects the human disease68,76-78. 
 Although it is clear that the aberrant expression of ERG or ETV1/4/5 
genes contributes to prostate cancer progression, the description of molecular 
mechanisms that facilitate this phenotypic response are incomplete. Due to the 
central role of the androgen receptor (AR) in the etiology and treatment of 
prostate cancer79,80, the interplay of ETS factors and AR has been a focus of 
many studies. ERG and ETV1 physically interact with AR and act as pioneer 
factors to expand AR’s binding to new genomic loci74,76,77,81. Whereas ETV1 and 
AR synergize to drive higher transcriptional output74,77, ERG appears to dampen 
the transcriptional affect of AR alone77,81. This difference may be due, at least in 
part, to ETV1 driving prostate cell-autonomous production of the androgen 
hormone. ETS factors normally expressed in the prostate, such as SPDEF and 
ELF3, also interact with and perturb the transcriptional activity of AR82,83. 
Therefore, multiple ETS factors are capable of influencing the location and 
transcriptional activity of AR, and the overexpression of ERG or ETV1, may drive 
prostate cancer by disrupting the normal ETS-AR balance in normal prostate 
cells by altering the location and activity of AR. 
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Activator protein 1 (AP1) is a heterodimeric transcription factor composed 
of JUN and FOS subunits. ETS – AP1 is a transcription factor partnership that 
has more clearly illustrated the opposite roles of ETS factors in prostate cancer. 
ERG, ETV1, and ETV4 drive the transcription of genes that are near composite 
ETS-AP1 sites, whereas SPDEF and EHF repress the transcription of these 
genes64,84. These ETS-AP1 composite sites are near genes that are important for 
cell migration, such as matrix metalloproteases and the extracellular matrix 
remodeler urokinase plasminogen activator84,85. Concordantly, overexpression of 
ERG, ETV1, or ETV4 is sufficient for the increased migration of normal prostate 
cells. There is also specificity from the AP1 side as the JUN proteins cJUN, 
JUNB, and JUND differentially regulate transcription at ETS-AP1 composite 
sites86. While it is clear that the tumor suppressor ETS factors, EHF and SPDEF, 
as well as oncogenic ETS factors, ERG, ETV1, and ETV4, regulate ETS-AP1 
composite sites in an opposing manner, the molecular basis for this distinction is 
unclear. 
 
Targeting transcription factors for inhibition 
The deviant expression or activity of transcription factors is characteristic 
of many human cancers, making misregulated transcription factors desirable 
therapeutic targets2,87,88. However, several intrinsic characteristics of transcription 
factors make therapeutic intervention difficult. With the exception of nuclear 
hormone receptors80,89, transcription factors do not possess highly concave 
ligand pockets that have served as energetically favorable targets in proteins 
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such as kinases90 or chromatin modifying enzymes91,92. Rather, the DBD of 
transcription factors presents a broad surface for extensive DNA contact and is 
highly conserved throughout transcription factor families (Fig. 1.2), making 
potent, yet selective inhibition of this interface a challenge. Transcription factors 
make numerous protein-protein contacts with transcriptional cofactors29 (Fig. 
1.1c), therefore prior knowledge of which, if any, of these interactions is 
necessary for the disease state is required. Additionally, much like protein-DNA 
interactions, protein-protein interfaces typically form broad interfaces that are 
difficult to selectively inhibit. Despite these challenges, progress has been made 
in inhibiting transcription factors through modulation of expression or protein 
stability and through blocking protein-protein interfaces. 
 Inhibitors of the bromodomain and extraterminal (BET) protein BRD4, a 
transcriptional coactivator, competitively compete with acetylated transcription 
factors and histone tails to bind with BRD493,94. These inhibitors are active in 
many forms of hematological and solid cancers95-97. Originally, the mode-of-
action for BRD4 inhibitors was thought to be the reduced transcription of the 
oncogenic transcription factor MYC95,97. In many cancers, down-regulation of 
MYC is, at least in part, responsible for the effect of BRD4 inhibition. However, in 
other cancer subtypes, BRD4 inhibition appears to be completely independent of 
the transcription and expression of MYC98. Therefore, BRD4 inhibition serves as 
an example of decreasing the expression of a transcription factor and/or of 
blocking a transcriptionally important protein-protein interface, depending on the 
disease context. 
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 ERG, as discussed above, is overexpressed in the majority of prostate 
cancer patients53,68. The inhibition of a deubiquitinase enzyme, ubiquitin-specific 
peptidase 9 X-linked (USP9X), that deubiquinates ERG results in ERG 
degradation and inhibits growth of ERG-positive tumors in mouse xenograft 
models of prostate cancer99. Conjugation of a phthalimide-derived molecule to 
JQ1, one of the BRD4 inhibitors discussed above, increases BRD4 protein 
degradation through recruitment of the cereblon (CRBN) E3-ubiquitin ligase, and 
is efficacious in a mouse model of leukemia100. A distinct phthalimide-derived 
molecule has anticancer activity against multiple myeloma cell lines and patient 
cells by specifically decreasing the protein levels of the Ikaros family zinc finger 
transcription factors 1 and 3 through a similar mechanism101. In the opposite 
direction, inhibition of the E3-ubiquitin ligases MDM2 or MDM4 increases the 
stability of the tumor suppressor p53 and improves survival in mouse models of 
lymphomas, sarcomas, and liver carcinomas102-104. Therefore, modulating the 
expression of oncogenic or tumor suppressor transcription factors appears to be 
a tractable method for the targeted treatment of many cancers. 
 Other strategies have focused on the inhibition of protein-protein 
interfaces that are crucial for disease phenotype. An inhibitor that blocks the 
interaction between transcription factors CBFβ and RUNX1 delays leukemia 
progression in mice105. CBFβ/SMMHC chromosomal rearrangements in acute 
myeloid leukemia result in an aberrant trifold symmetry in the CBFβ-RUNX1 
interaction, and the inhibitor mimics this additional symmetry in order to 
specifically inhibit CBFβ/SMMHC - RUNX1 interactions over wild-type CBFβ – 
	   11	  
RUNX1 interactions. Disruption of ELF3 with MED23 decreased the expression 
of the HER2 oncoprotein and specifically inhibited the cell-growth of HER2-
expressing breast cancer cell lines106-108. Therefore, the inhibition of protein-
protein interactions required for disease progression is another viable strategy for 
targeting transcription factors.  
 
Summary of research chapters 
The common misregulation of transcription factor expression and activity 
in cancers makes these factors attractive, yet difficult, therapeutic targets. The 
challenges of, as well as previous successes in, inhibiting transcription factors 
indicate that elucidation of the mechanisms by which these proteins contribute to 
cancer can be leveraged into generating more selective inhibitors. Chapter 2 
describes the development of an assay that is amenable to high-throughput 
screening for small molecule inhibitors for the interaction of ETS1 and DNA. The 
lead compound from this screen was nonspecific in inhibiting ETS and other 
transcription factors, but the screen is robust in differentiating between positive 
and negative hits and is transferrable to other ETS factors with roles in cancer 
progression.  Chapter 3 details the characterization of DNA-binding autoinhibition 
in the ETV1/4/5 subfamily of transcription factors. An intrinsically disordered 
region and an α-helix cooperatively inhibit the DNA binding of the ETS domain of 
ETV4 by modulating the positioning of the DNA-recognition α-helix. Acetylation of 
lysine residues within the intrinsically disordered region ablates autoinhibition, 
suggesting that this is a route for the in vivo regulation of ETV4 DNA binding.  
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The involvement of activation and DNA-binding domains of ETV4 in the 
interaction with MED25 is identified in Chapter 4. Divergent sequences within the 
ETS domain, and a secondary structural element that is specific to the ETV1/4/5 
subfamily form the DNA-binding domain interaction surface of the ETV4-MED25 
interaction, thereby dictating the specificity of MED25 for ETV4 as compared to 
other ETS factors. Chapter 5 reveals that cJUN-FOS cooperates with, or 
antagonizes, the DNA-binding of ERG and EHF, respectively. This distinction 
supports the differential regulation of ETS-AP-1-controlled genes by these 
factors, and may underlie their distinctive phenotypes in the context of prostate 












Figure 1.1 Eukaryotic transcription preinitiation complex. (a) Cartoon depicting 
eukaryotic transcription preinitiation complex including RNA polymerase II (Pol 
II), general transcription factors, gene regulatory proteins or transcription factors, 
and the Mediator complex. Image from Alberts et al., 2014. (b) Cartoon depiction 
of a sequence-specific transcription factor illustrating two minimal domains; a 
DNA-binding domain, DBD, red, and an activation domain, AD, blue. (c) The 
structure of IFN-B enhancer10	  is an example of an enhanceosome, or a region of 
DNA where multiple transcription factors bind to modulate Pol II recruitment and 
activity at a gene. Image from Panne et al., 2007. (d) The AD of p53 has unique 
secondary structural characteristics depending on the individual coactivator. 


















Figure 1.2 ETS family of transcription factors. Left, ETS transcription factors are 
depicted as rectangles with red, green, blue, and purple boxes depicting ETS, 
PNT, OST, and B-box domains, respectively. Light blue circles denote ETS 
factors that are overexpressed in prostate cancer. Right, structure of ETV4 ETS 
domain with the protein backbone in cartoon format and amino acid side chains 
in stick format. Individual amino acids are colored according to their conservation 
in all human ETS domains. N and C refer to the N-terminus and the C-terminus 
of the ETS domain, and H1, H2, H3 and S1, S2, S3, S4 refer to the α-helices and 
β-strands in order from N- to C-terminus. Rectangle depiction of ETS factors 
modified from Hollenhorst et al., 2011. 
  
















Figure 1.3 Structurally characterized examples of DNA-binding autoinhibition in 
ETS factors. ETS147,48,53, ERG51, and ETV637,49,50 are examples of ETS factors 
with inhibitory sequences, cyan, that have been structurally characterized. The 
conserved ETS domain is colored red. The serine-rich region (SRR) inhibitory 
element in ETS1 is represented as a dotted line as it is intrinsically disordered 
and does not take on a fixed position or structure while inhibiting the ETS 
domain.	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Abstract 
 
ETS transcription factors from the ERG and ETV1/4/5 subfamilies are 
overexpressed in the majority of prostate cancer patients and contribute to 
disease progression. Here, we developed an in vitro assay for ETS transcription 
factors binding to DNA that is amenable to high-throughput screening. Using 
ETS1 as a model for ETS transcription factors, we applied these assays to 
screen 110 compounds that were derived from a high-throughput virtual screen. 
We find that lower affinity DNA binding sites, similar to those which ERG and 
ETV1 bind to in prostate cells, allow for higher inhibition from many of these test 
compounds. Additionally, we demonstrate that these assays are robust for the 
ETS transcription factors that are overexpressed in prostate cancer, such as 
ERG, ETV1, and ETV5. 
 
Introduction 
DNA sequence-specific transcription factors influence RNA polymerase 
activity in a gene-specific manner and are among the major factors that regulate 
normal development and define cellular fate. Transcription factors are often 
misregulated in human cancers, with the most abundant examples being the 
downregulation of the p53 tumor suppressor and upregulation of the C-MYC 
oncoprotein1. From this perspective, transcription factors are highly desirable 
therapeutic targets. Yet, with the exception of steroid hormone receptors, 
transcription factors are difficult therapeutic targets due to the lack of highly 
concave ligand-binding surfaces. However, there are some successful examples 
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of modulating the DNA occupancy of transcription factors through the inhibition of 
protein-protein interfaces2,3.  
 The ETS family of transcription factors contains 28 genes in humans that 
possess a conserved ETS DNA-binding domain (Fig. 2.1a). Factors of the ERG 
(ERG, FLI1, FEV) and PEA3 (ETV1, ETV4, ETV5) subfamilies are involved in 
chromosomal rearrangements that result in the overexpression of these proteins 
in the majority of prostate cancer patients4. Preclinical modeling of prostate 
cancer suggests that the overexpression of ERG, ETV1, or ETV4 contributes to 
further disease progression5,6, indicating that these transcription factors are 
desirable therapeutic targets. 
 Here we have designed in vitro DNA-binding assays for ETS transcription 
factors that are amenable to high-throughput screening. We piloted these assays 
using ETS1 and a library of 110 compounds derived from high-throughput virtual 
screening. Furthermore, we demonstrate that using lower affinity ETS DNA 
binding sites, similar to those bound by ERG and ETV1 in prostate cells, raises 
the efficacy of inhibitors of ETS–DNA interactions. Lastly, we establish that these 
in vitro assays can be used with the prostate-cancer relevant transcription factors 
ERG, ETV1, and ETV5. 
 
Results  
ETS1 DN279 (amino acids 279 – 441) was used to pilot in vitro assays 
that could be utilized for high-throughput screening of potential small molecule 
inhibitors of ETS-DNA interaction. This fragment has robust expression in a 
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recombinant system and contains the same affinity for DNA as full-length ETS17. 
The ETS domains of ETS1, ERG, and ETV1 are conserved from an amino-acid 
sequence and structural perspective (Fig. 2.1a and Fig. 2.2a). Therefore, ETS1 
serves as a good model for the DNA-binding of these other ETS factors and 
inhibitors that prevent ETS1 from binding to DNA would likely also inhibit ERG 
and ETV1. 
 ETS1 DN279 was expressed in E. coli and thoroughly purified using a Ni2+ 
affinity column, a cation exchange column, and a size exclusion column (Fig. 
2.2b). Using electrophoretic mobility shift assay (EMSA) we measured the 
binding of   ETS1 DN279 to DNA with a consensus ETS site (5’-CCGGAAGT-3’), 
termed SC1 (Selected Clone 1)8. The KD of 0.4 nM is in agreement with previous 
measurements for this fragment (Fig. 2.2c)9. The yield of ETS1 DN279 was 
generally around five milligrams of purified protein per liter of bacterial culture, 
which provided plenty of protein for this study and could be efficiently scaled up 
to provide enough protein for a high-throughput screen.  
 We next optimized screening conditions with the validated ETS1 DN279 
for two potential high-throughput assays: fluorescence polarization, and 
ALPHAScreen.  The fluorescence polarization assay utilized a fluorescein-tagged 
SC1 DNA and measures the change in the polarization of fluorescently emitted 
light when the DNA is free in solution versus when the DNA is bound by a 
transcription factor. The ALPHAScreen assay brings beads that engage in 
fluorescence resonance energy transfer (FRET) into proximity through 
conjugation to a transcription factor and its recognition DNA site using Ni2+-His6 
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and streptavidin-biotin interactions, respectively. First, titration of either DNA 
demonstrated that using 5 nM of fluorescein-tagged DNA for fluorescence 
polarization or 10 nM of biotin-tagged DNA for ALPHAScreen minimized the 
amount of DNA while still retaining a large signal in these assays with ETS1 
DN279. Using these amounts of DNA, titration of ETS1 DN279 showed a dose-
dependent response in these two assays with a concentration of around 30-50 
nM generating maximum signal (Fig. 2.1b,c). Based on these titrations, 10 nm 
concentrations of ETS1 DN279 were used in the fluorescence polarization and 
ALPHAScreen assays, respectively, for compound screening studies. The 
maximum signal and the baseline were used to calculate a Z’ factor for these 
assays. The fluorescence polarization assay had a Z’ factor of 0.4 and the 
ALPHAScreen assay had a Z’ factor of 0.7. Z’ factors above 0.5 are considered 
to be excellent assays for high-throughput screening purposes10. Whereas the 
ETS1 ALPHAScreen assay already clears this guideline, the ETS1 fluorescence 
polarization assay is close and could likely be optimized to achieve Z’ factors 
over 0.5. 
 Computer modeling was utilized to enrich for likely bioactive compounds in 
the limited number of compounds to be screened using these newly established 
in vitro assays. Briefly, PocketFinder (ICM) and SiteMap (Schrödinger) were 
used to define ligand-binding pockets in the ETS domain of ETS1 (Fig. 2.3). 
Sequential rounds of virtual screening using one of these defined ligand-binding 
pockets, ETS1 site 1, culled a starting library of 13 million compounds down to 
110 compounds to be tested in the in vitro ETS1 DNA binding assays. In addition 
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to the predicted strength of interaction with ETS1, these compounds were also 
filtered to optimize chemical diversity and enrich for compounds with favorable 
physicochemical properties. 
 A constant concentration of protein and DNA, as indicated above, was 
used to test the inhibition of each of the 110 compounds that resulted from virtual 
screening. These compounds were tested at a single concentration of 60 mM 
and each compound or control was measured in quadruplicates. Using three 
standard deviations above the baseline (3-SD) as a cutoff, only two compounds 
in the fluorescence polarization assay and four compounds in the ALPHAScreen 
assay significantly inhibited the ETS1 DN279 – DNA interaction. Only one of 
these compounds significantly inhibited this interaction in both assays (Fig. 2.4a).  
To further investigate these compounds, as well as some additional 
compounds that were close to the 3-SD cutoff, we utilized the ‘TruHits’ false 
positive screen in ALPHAScreen. In this assay, a small molecule that covalently-
conjugates biotin and His6 together is used in lieu of the biomolecules of interest, 
in this case ETS1 DN279 and SC1 DNA. Compounds that inhibit the false 
positive assay must do so through a manner inherent to the assay itself such as 
by absorbing light in the donor or emission wavelengths or by disrupting the 
streptavidin-biotin or His6 - Ni2+ interactions that conjugate the biomolecules to 
the ALPHA beads. All of the compounds that strongly inhibited the ALPHAScreen 
assay also strongly inhibited this false positive assay (Fig 2.4b). Only two 
compounds that had weak to moderate inhibition of the ALPHAScreen assay 
displayed differential preference for inhibiting the ALPHAScreen assay more 
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robustly than the false positive assay.  
With very few, if any, actual hits from our first round of in vitro screening, 
we next considered potential adjustments to our assays. One potential challenge 
with this screen is that strength of the ETS1 DN279 – SC1 DNA (KD = 0.4 nM) 
interaction might conceal the discovery of lead compounds with relatively lower 
affinity for ETS1 DN279, which then could be further optimized for inhibition. To 
address this, we switched from SC1 (5’-GCCGGAAGTG-3’), the highest affinity 
DNA sequence for ETS1, to a weaker ETS1 binding site, SC13 (5’-
ACAGGATATC-3’) 8. By EMSA, ETS1 DN279 bound to SC13 with KD of 3 nM. 
This roughly 10-fold weaker interaction is consistent with the difference observed 
between SC1 and SC13 DNA with other ETS1 truncations8. 
We rescreened the 110 compounds against ETS1 and SC13 DNA. 
Eighteen of these compounds inhibited the ETS1-SC13 interaction above the 3-
SD cutoff, as compared to only four for the ETS1-SC1 interaction (Fig. 2.5a). 
While many of these compounds still inhibited the ‘TruHits’ false positive assay, 
12/20 compounds showed more inhibition in the ETS1-SC13 assay than the false 
positive assay (Fig. 2.5b), compared to only 2/12 compounds that showed more 
inhibition in the ETS1-SC1 assay than the false positive assay (Fig. 2.4b). 
Therefore, using the weaker interaction of ETS1 with SC13 DNA appears to 
enable more compounds to disrupt this interaction. Additionally, a significant part 
of the inhibition observed in the ALPHAScreen assays for most of these 
compounds appears to come from “off-target” effects in the assay, besides 
interrupting the ETS-DNA interaction. However, as several of these compounds 
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display stronger inhibition of the ETS1-SC13 assay than the false positive assay, 
these compounds may inhibit the ETS1-DNA interaction in addition to the 
ALPHAScreen assay in general. 
In both the ETS1-SC1 and ETS1-SC13 screens, the same compound, 
CIT-0312, displayed the largest differential between inhibition of ETS1 DN279-
DNA assays and inhibition of the false positive assay. Therefore, this compound 
displayed the most inhibition of the ETS – DNA interaction, as opposed to 
inhibiting other components of the ALPHAScreen assay. Additionally, CIT-0312 
more robustly inhibited the ETS-SC13 interaction (73%) than the ETS-SC1 
interaction (36%), as would be expected given the relatively weaker affinity of the 
ETS-SC13 interaction. This compound inhibited ETS1 DN279 – SC13 DNA 
interaction in the ALPHAScreen assay with an IC50 of 8.0 ± 0.3 mM (mean ± 
standard deviation). To confirm this inhibition, we tested CIT-0312 using EMSAs. 
In this orthogonal assay, CIT-0312 inhibited the ETS1 DN279 – SC1 DNA with 
an IC50 of 27 ± 5 mM (mean ± standard deviation) (Fig. 2.6).  Further 
investigation demonstrated that this compound lacked specificity as it similarly 
inhibited cJUN-FOS and FOXA1 transcription factors from binding to their 
cognate DNA recognition sites. Therefore, this particular compound must be 
inhibiting the DNA binding of ETS1, as well as other transcription factors, through 
a nonspecific mechanism that is distinct from the prediction of our in silico 
modeling (Fig. 2.3). 
 Within the ETS family of transcription factors, ERG and ETV1/4/5 
subfamily proteins are overexpressed in a number of cancers, including prostate 
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cancer4, making therapeutic inhibition of these proteins desirable. To establish 
that the screening assays used here for ETS1 are suitable for these proteins we 
expressed and purified full length, His6-tagged ERG, ETV1, and ETV5. Titrations 
of these proteins with 10 nM of biotin-tagged SC1 DNA and streptavidin donor 
and nickel chelate acceptor beads established that these proteins similarly 
generate robust ALPHAScreen signal, with a maximum signal observed around 
20-70 nM, depending on the individual protein (Fig. 2.7). Each of these 
interactions had Z’ factors over 0.5 (ERG, 0.8; ETV1, 0.6; ETV5, 0.8), suggesting 
that they would be suitable for high-throughput screening.  
 
Discussion 
In summary, we have established that two in vitro assays, ALPHAScreen 
and fluorescence polarization, are suitable for high-throughput screening of 
potential small molecule inhibitors of ETS1–DNA interactions. Using weaker 
affinity DNA, such as SC13, was advantageous for more readily identifying lead 
compounds from our screens. Interestingly, these nonconsensus DNA sites may 
be more desirable biologically as well as they more closely resemble the ERG 
and ETV1 DNA-binding sites that are relevant in prostate cancer5,6,11. In contrast, 
consensus ETS sites, such as SC1, are redundantly regulated by multiple ETS 
factors and control the expression of housekeeping genes12. Lastly, we have 
demonstrated that ETS factors with high clinical relevance, such as ERG and 
ETV1, can be used in these screening assays. 
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 Methods 
DNA constructs 
Human cDNAs corresponding to full-length ETV1, ETV5, and ERG were 
cloned into the bacterial expression vector pET28 (Novagen) using standard 













ETS1 DN279 construct in pET28 was cloned as previously described 7. 
 
Expression and purification of proteins 
All proteins were produced in Escherichia coli (lDE3) cells. ETS1 DN279 
efficiently expressed into the soluble fraction. Cultures of 1 L Luria broth (LB) 
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were grown at 37 °C to OD600 ~ 0.7 - 0.9, induced with 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG), and grown at 30 °C for ~ 3 hours. 
Harvested cells were resuspended in 25 mM Tris pH 7.9, 1 M NaCl, 5 mM 
imidazole, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM 2-
mercaptoethanol (BME), and 1 mM phenylmethanesulfonylfluoride (PMSF). Cells 
were lysed by sonication and centrifuged at 40k rpm for at least 30 minutes at 4 
°C. After centrifugation, the soluble supernatants were loaded onto a Ni2+ affinity 
column (GE Biosciences) and eluted over a 5-500 mM imidazole gradient. 
Fractions containing purified protein were pooled and dialyzed overnight at 4 °C 
into 25 mM Tris pH 7.9, 10% glycerol (v:v), 1mM EDTA, 50 mM KCl, and 1 mM 
dithiothreitol (DTT). After centrifugation at 40k rpm for 30 minutes at 4 °C, the 
soluble fraction was loaded onto a SP sepharose cation exchange column (GE 
Biosciences) and eluted over a 50-1000 mM KCl gradient. Fractions containing 
the ETS proteins were loaded onto a Superdex 75 gel filtration column (GE 
Biosciences) and eluted fractions were analyzed by SDS-PAGE for purified ETS 
proteins. The final, purified protein was then concentrated on a 10-kDa molecular 
weight cut-off (MWCO) Centricon device, snap-frozen in liquid nitrogen, and 
stored at -80°C in single-use aliquots for subsequent in vitro studies. 
Full-length ERG, ETV1, and ETV5 generally expressed more efficiently in 
the insoluble fraction using IPTG induction as described above. Harvested cells 
were resuspended as described above, sonicated and centrifuged at 15k rpm for 
15 minutes at 4 °C. The soluble fraction was discarded and this procedure was 
repeated with the pellet / insoluble fraction twice more to rinse the inclusion 
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bodies. The final insoluble fraction was resuspended with 25 mM Tris pH 7.9, 1 
M NaCl, 0.1 mM EDTA, 5 mM imidazole, 2 mM BME, 1 mM PMSF, and 6 M 
urea. After sonication and incubation for ~ 1 hour at 4 °C, the sample was 
centrifuged for 40k rpm for at least 30 minutes at 4 °C. The soluble fraction was 
loaded onto a Ni2+ NTA affinity column (GE Biosciences) and refolded by 
immediately switching to a buffer with the same components as above except 
lacking urea. After elution with 5 to 500 mM imidazole, the remaining purification 
steps, ion-exchange and size-exclusion chromatography, were performed as 
described above. However, a Q sepharose anion-exchange column was used 
instead of a SP sepharose cation-exchange column due to differing isoelectric 
points of the full-length proteins compared to ETS1 DN279. 
Protein concentrations were measured using averages from the following 
two methods after ensuring that the concentrations from each method were in 
agreement with one another (within ~ 2 fold).  
Protein concentrations were determined by measuring the absorbance at 
595 nm of 20 uL of protein combined with 1 mL of Protein Assay Dye Reagent 
(diluted 1:5 in deionized water)(Bio-Rad) and comparing to a bovine serum 
albumin standard curve. Molecular weights for each ETS protein were calculated 
using the Peptide Property Calculator (Northwestern).  
Additionally, absorbance at a wavelength of 280 nm was measured on 
samples of protein mixed with 6M Guanidine HCl (Thermo Scientific) at a 1:1 
ratio and compared to a blank. Protein concentrations were determined using 
Beer’s Law (Abs280nm = ε*l*c) with extinction coefficients for each protein 
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calculated using Peptide Property Calculator (Northwestern).  
 
Electrophoretic mobility shift assays (EMSAs)  
DNA-binding assays of ETS factors utilized duplexed 27-bp 
oligonucleotides with a consensus ETS binding site:  5’-
TCGACGGCCAAGCCGGAAGTGAGTGCC-3’ (arbitrarily assigned as “top” 
strand) and 5’-TCGAGGCACTCACTTCCGGCTTGGCCG-3’ ("bottom" strand).  
Boldface GGAA indicates the consensus ETS binding site motif. 0.2 nanomoles 
of each of these oligonucleotides, as measured by absorbance at 260 nM on a 
NanoDrop 1000 (Thermo Scientific), were labeled with [g-32P] ATP (Perkin 
Elmer) using T4 polynucleotide kinase (Thermo Scientific) at 37° C for ~ 30-60 
minutes.  After purification over a Bio-Spin® 6 chromatography column (Bio-
Rad), the combined oligonucleotides were incubated at 100 °C for ~ 5 minutes, 
and then cooled to room temperature over 1-2 hours. For binding reactions, the 
DNA concentration was diluted to 1 x 10-11 M and held constant, whereas protein 
concentrations ranged ~ 6 orders of magnitude with the exact concentration 
range dependent on the KD of the particular protein fragment. Protein 
concentration was determined after thawing each aliquot of protein, as described 
above. The binding reactions were incubated for 3 hours at 4° C in a buffer 
containing 25 mM Tris pH 7.9, 0.1 mM EDTA, 60 mM KCl, 6 mM MgCl2, 200 
mg/mL BSA, 10 mM DTT, 2.5 ng/mL poly(dIdC), and 10% (v:v) glycerol and then 
resolved on an 8% (w:v) native polyacrylamide gel at 4 °C. The 32P-labeled DNA 
was quantified on dried gels by phosphorimaging on a Typhoon Trio Variable 
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Mode Imager (Amersham Biosciences). Equilibrium dissociation constants (KD) 
were determined by nonlinear least squares fitting of the total protein 
concentration [P]t versus the fraction of DNA bound ([PD]/[D]t) to the equation 
[PD]/[D]t = 1/[1 + KD/[P]t)] using Kaleidagraph (v. 3.51; SynergySoftware). Due to 
the low concentration of total DNA, [D]t, in all reactions, the total protein 
concentration is a valid approximation of the free, unbound protein concentration.  
 
Computational methods 
Computational methods were used as previously described13. All 
computational studies used PDB ID 2NNY14 for the structural coordinates of 
ETS1. PocketFinder (ICM) and SiteMap (Schrödinger) were used to define 
ligand-binding sites. Out of the three ETS1 protein and one DNA ligand-binding 
sites that were defined by PocketFinder and SiteMap, only ETS1 site 1 (Fig. 2.3) 
was used for docking studies.  
 The compound database was prepared using Ligprep 2.1.23 of the 
Schrödinger Suite and ICM’s inbuilt preparation of three-dimensional ligands. A 
small molecule ligand library of 13 million compounds was docked against ETS1 
using Glide High Throughput Virtual Screen.  The top ~ 15% ranked compounds 
were then redocked with the relatively more computationally expensive Glide 
standard precision scoring. The top ~ 0.5% ranked were then subjected to further 
virtual screening using Glide extra-precision and ICM docking and scoring 
methods. 
The final compounds that were identified for in vitro screening were the 
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top ranking compounds from this final round of virtual screening that also met 
certain physicochemical criteria, such as solubility > 50 mg/mL, permeability > 50 
nmol/s, and polar surface area < 120 Å2 as determined by QikProp. In addition to 
these rankings, redundant compounds were removed using ICM Molcart to 
improve the chemical diversity of the final set of compounds. Visual inspection of 
the docking results was used to evaluate binding mode, position, and orientation. 
In sum, this process resulted in 110 compounds that were purchased and 
screened using in vitro ETS1 DNA-binding assays. 
 
Fluorescence polarization 
Fluorescence polarization reactions were performed in the same buffer as 
described above for EMSAs. Reactions were carried out in 20 mL volumes in 
black 384 well plates (Corning). The protein, DNA, and compound were 
incubated for 30 minutes at room temperature, protected from light. Timecourse 
studies demonstrated that less than 5 minutes were required for the protein-DNA 
reaction to reach equilibrium; however, we went with a longer incubation time to 
encourage compound – protein interactions, potentially with significantly lower 
affinity and kinetics, to also reach equilibrium. Reactions containing up to 5% 
DMSO showed no influence on the DNA-protein interaction. Plates were then 
analyzed on an Envision 2104 Multilabel Reader (Perkin Elmer). To calculate 
percent inhibition, the signal (mp) for each compound was compared to positive 
(10 nM protein, 5 nM DNA, 0 mM compound; set to 0% inhibition) and negative 
(0 nM protein, 5 nM DNA, 0 mM compound; set to 100% inhibition) controls. 
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 ALPHAScreen 
ALPHAScreen reactions were performed in the same buffer as described 
above for EMSAs except without 10% glycerol as this caused aggregation of the 
ALPHA beads. Reactions were carried out in 25 mL volumes in 384 well white 
OptiPlate-384 HB plates (Perkin Elmer). ALPHAScreen was performed according 
to manufacturer’s recommendations. Briefly, protein, compound, and DNA were 
incubated at room temperature for 60 minutes, protected from light. Nickel 
chelate acceptor beads were then added followed by another 60-minute 
incubation at room temperature, protected from light. Then streptavidin donor 
beads were added followed by another 60-minute incubation at room 
temperature. Plates were then analyzed on an Envision 2104 Multilabel Reader 
(Perkin Elmer). To calculate percent inhibition, the signal (cps) for each 
compound was then compared to positive (10 nM protein, 10 nM DNA, 0 mM 
compound; set to 0% inhibition) and negative (0 nM protein, 10 nM DNA, 0 mM 
compound; set to 100% inhibition) controls. 
 
Comparison of fluorescence polarization and ALPHAScreen assays 
In order to compare the assay performance between fluorescence 
polarization and ALPHAScreen assays for ETS1, the following equation was 
used to calculate a Z’ factor (µ and σ are mean and standard deviation and c+ 
and c- are positive and negative controls) 10: 
𝑍′ = 1− 3𝜎!! + 3𝜎!!𝜇!! − 𝜇!!  






Figure 2.1 ETS1-DNA interaction in fluorescence polarization and ALPHAScreen 
assays. (a) Structural alignment of ETS domains from ETS1 (PDB: 2NNY), ERG 
(4IRI), and ETV1 (4BNC) bound to DNA. H1, H2, and H3 indicate the order of 
the α-helices in the ETS domain from N-terminus to C-terminus, according to 
previous nomenclature. (b) Fluorescence polarization assay with a titration of 
ETS1 DN279 and 5 nM of 3’ fluorescein-labeled SC1 DNA. (c) ALPHAScreen 
assay with a titration of ETS1 DN279 and 10 nM of 5’ biotin-labeled SC1 DNA. 





















































Figure 2.2 Purification and validation of ETS1 protein. (a) Sequence alignment of 
ETS domain from ETV1, ERG, and ETS1. Coloring of amino acid sequence 
according to Clustal Omega. Rectangles and arrows above sequence alignment 
refer to α-helices and β-strands, respectively. Arrows below the sequences 
indicate amino acids that make contact with DNA (Hydrogen bonds, salt bridges, 
or hydrophobic contacts). (b) Coomassie-stained gel of purification of ETS1 
DN279. Lanes: (1) marker, (2) soluble fraction, (3) Ni2+ affinity flow-through, (4) 
Ni2+ affinity elution, (5) heparin load, (6) heparin flow-through, (7) heparin elution, 
(8) size-exclusion load, (9) size exclusion peak, (10) size-exclusion peak, 5x 
quantity in lane 9. (c) Electromobility shift assay with ETS1 DN279 and 32P-
labelled SC1 DNA. The measured KD of 0.38 nM is in agreement with literature 
values (0.44 ± 0.04 nM)9.  
  































Figure 2.3 Computational modeling of potential inhibitor binding sites on ETS1-
DNA interaction. PocketFinder (ICM) and SiteMap (Schrödinger) were used to 
define the ligand-binding site for docking studies. Only ETS1 site 1 was used for 
the virtual-screening of compounds in this report. The cartoon of ETS1-DNA 



























Figure 2.4 In vitro screen for inhibitors of ETS1 – SC1 DNA interaction by 
fluorescence polarization and ALPHAScreen. (a) 110 compounds identified from 
virtual screening were assayed for inhibition of ETS1 – SC1 DNA interaction 
using fluorescence polarization (DFP) and ALPHAScreen (ALPHA). Percent 
inhibition was calculated with reference to positive (protein and DNA, no 
compound) and negative (DNA only, no protein or compound) controls. Dotted 
gray lines indicate three standard deviations separation from the baseline for 
each assay. (b) Counterscreen of the top hits from ALPHAScreen assay using 
the TruHits false positive kit. Dotted gray line indicates where the percent 
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Figure 2.5 Screen for inhibitors of ETS1 – SC13 DNA interaction using 
ALPHAscreen. (a) Comparison of inhibition efficiency of compounds against 
ETS1 and SC1 DNA (x-axis) and ETS1 and SC13 DNA (y-axis). SC13 is a lower-
affinity ETS binding site. Horizontal and vertical dotted gray lines indicate three 
standard deviations separation from the baseline for each screen. Diagonal, 
finely dotted line indicates where the inhibition against both of these DNA 
sequences is equal. (b) Counterscreen of the top hits from ETS1-SC13 assay 
using the TruHits false positive kit. Dotted gray line indicates where the percent 
inhibition of the ALPHAScreen assay and the false positive assay are equal. 
Arrow indicates the compound with the largest differential of inhibition of ETS-
DNA assay compared to false positive assay, and was used for further studies. 
(c) Representative titration of compound CIT-0312 using ALPHAScreen assay 
with ETS1 DN279 and SC13 DNA. Indicated IC50 of 8.0 ± 0.3 mM (mean ± 







Figure 2.6 EMSA confirmation of compound inhibition. Left, representative 
titration of CIT-0312 against ETS1 DN279 and SC1 DNA using EMSA. Right, plot 
of ETS1 DN279 bound to DNA versus total DNA (PD/Dt) against CIT-0312 
concentration. Indicated IC50 of 27± 5 mM (mean ± standard deviation) for this 
compound was calculated from three replicate experiments. 
  
































































IC50 = 8.0 ± 0.3 μM

























Figure 2.7 ERG-, ETV1-, and ETV5-DNA interactions in the ALPHAScreen 
assay. ALPHAScreen assay with a titration of ERG (top), ETV1 (middle), or 
ETV5 (bottom) and 10 nM 5’ biotin-labeled SC1 DNA.  
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Abstract 
 
The ETS transcription factors ETV1, ETV4, and ETV5 are often 
overexpressed in prostate cancer. Here we described the molecular basis of 
DNA-binding autoinhibition of these factors. Inhibitory elements that cooperate to 
repress DNA binding were identified in regions N- and C-terminal of the ETS 
domain. Crystal structures of these three factors revealed an α-helix in the C-
terminal inhibitory domain that packs against the ETS domain and perturbs the 
conformation of its DNA-recognition helix. NMR spectroscopy demonstrated that 
the N-terminal inhibitory domain is intrinsically disordered, yet utilizes transient 
intramolecular interactions with the ETS domain and the C-terminal inhibitory 
domain to mediate autoinhibition. Our studies reveal a distinctive mechanism for 
DNA-binding autoinhibition in the ETV1/4/5 subfamily of ETS proteins and 




Autoinhibition occurs in diverse proteins and allows for spatiotemporal 
modulation of activity in response to various inputs such as signaling pathways 
and macromolecular partnerships1. This self-dampening activity can influence the 
equilibria between the active and inactive states of proteins by serving as the 
integration point for posttranslational modifications and protein interactions. 
Alternative intramolecular and intermolecular interactions are often the key 
attribute for an autoinhibitory element2,3. Notably, both structured elements and 
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intrinsically disordered regions (IDR) can be effective inhibitory elements4. 
However, conformational disorder allows for distinct and adaptable recognition of 
both intramolecular surfaces and diverse interacting proteins5. IDR function in 
autoinhibition adds to the growing evidence for significant roles for disorder in 
protein function, thereby regulating cellular processes, including transcription6. 
The ETS gene family, which encodes 28 human transcription factors 
(reviewed in7), provides a model system to expand our understanding of the role 
of IDRs in autoinhibition. Autoinhibition of the conserved DNA binding domain, 
termed the ETS domain, is reported for multiple family members. In the case of 
ETS1, the most thoroughly characterized example, a serine-rich IDR inhibits 
DNA binding through transient phosphorylation-enhanced interactions with the 
structured ETS domain and flanking N- and C-terminal inhibitory α-helices8,9. 
However, distinct modes of autoinhibition, involving IDRs and appended helices, 
have been reported for members of different ETS subfamilies10-13 that lack the 
serine-rich IDR and flanking α-helices of ETS1. Autoinhibition of a particular ETS 
factor is also regulated by a distinct set of posttranslational modifications8,14 and 
protein-protein interactions15,16. Unique regulation corresponding to divergent 
modes of autoinhibition has been posited as one mechanism to account for 
specific gene regulation by individual ETS factors7,17.  
The involvement of the ETS genes of the ERG and ETV1/4/5 (also known 
as PEA3) subfamilies in prostate cancer motivated our interest in a better 
understanding of autoinhibition of these ETS factors. Chromosomal 
rearrangements involving ERG and ETV1/4/5 subfamilies are observed in the 
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majority of prostate cancer tumors9,18,19. There is aberrant expression of these 
full-length, or nearly full-length, ETS proteins upon rearrangement with a 
prostate-specific or a constitutively expressed promoter20. In addition, ETV1 and 
ETV4 mediate PI3-kinase and Ras signaling pathways, resulting in aggressive 
and metastatic disease phenotypes21,22. Although DNA-binding autoinhibition has 
been reported within the ETV1/4/5 subfamily11,16,23,24, detailed characterization is 
lacking. A mechanistic understanding of the autoinhibition of these factors may 
provide insights into their roles in prostate cancer progression and windows of 
opportunity for targeted therapeutic interventions.  
In this study, we describe the molecular basis of DNA-binding 
autoinhibition in the ETV1/4/5 subfamily of ETS factors. Using ETV4 as a model 
for this subfamily, we found that inhibitory domains reside both N- and C-terminal 
of the ETS domain and cooperate to inhibit DNA binding. Crystal structures 
identified the C-terminal inhibitory domain as an α-helix that packs against the 
ETS domain and perturbs the relative positioning of its DNA-recognition helix. 
NMR spectroscopy demonstrated that the N-terminal inhibitory domain is an IDR 
that transiently interacts with the ETS domain and the C-terminal inhibitory 
domain. Acetylation of the N-terminal inhibitory domain relieves autoinhibition, 
likely through disruption of its intramolecular interaction with the ETS domain and 
C-terminal inhibitory domain. From these findings, we propose a model for DNA-
binding autoinhibition in the ETV1/4/5 subfamily that evokes a conformational 
equilibrium modulated by interplay of structured and disordered sequences. 
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Results 
DNA binding by ETV1, ETV4, and ETV5 is autoinhibited  
We initially sought to determine the magnitude of autoinhibition in the ERG 
and ETV1/4/5 subfamilies of ETS factors. Towards this aim, we measured the 
DNA binding affinities (KD values), of the full-length proteins and nearly-minimal 
DNA-binding domains (DBD) for ERG, FLI1, ETV1, ETV4, and ETV5 (Fig. 3.1a). 
Robust autoinhibition was observed in ETV1, ETV4, and ETV5, with the full-
length proteins displaying ~10- to 30-fold weaker binding than their minimal 
DBDs (Fig. 3.1b-d and Table 3.1). These levels of autoinhibition are comparable 
to those previously reported for ETS18 and ETV610. In contrast, ERG and its 
subfamily member FLI1 displayed a modest 2- to 3-fold autoinhibition, as also 
previously reported11. Interestingly, the KD values cluster in a pattern that reflects 
their subfamily phylogenetic classifications (Fig. 3.1e)25. Based on the larger 
magnitude of autoinhibition observed with ETV1, ETV4, and ETV5, as compared 
to ERG and FLI1, we focused on the ETV1/4/5 subfamily for further mechanistic 
studies.  
We chose ETV4 as a model factor to further investigate autoinhibition in 
the ETV1/4/5 subfamily. Partial proteolysis aided the design of truncation 
boundaries for mapping inhibitory elements (Fig. 3.2a-c). We found that the 
predominant trypsin-resistant fragment, spanning amino acids 165-484, retained 
comparable levels of autoinhibition to full-length ETV4 (Fig. 3.3a and Table 3.2). 
Subsequent deletion studies revealed that amino acid residues both N- and C-
terminal of the ETS domain inhibit DNA binding independently, but synergize to 
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yield higher than additive levels of inhibition (Fig. 3.3b). Hereafter, these regions 
will be denoted as the NID (N-terminal inhibitory domain) and the CID (C-terminal 
inhibitory domain), whereas the nearly-minimal DBD will be denoted as an 
uninhibited species. Based on the autoinhibition mechanisms of other ETS 
proteins10,26, we hypothesized that the ETV1/4/5 NID and CID function through 
direct interactions with the ETS domain (or possibly with each other) to 
cooperatively inhibit DNA binding (Fig. 3.3c).  
 
An α-helix in the CID mediates autoinhibition 
To elucidate further the mechanism(s) of autoinhibition by the NID and 
CID, we undertook crystallographic studies on members of the ETV1/4/5 
subfamily. Structures for inhibited fragments of ETV1 and ETV4 (1.4 and 1.1 Å 
resolution data, respectively), which contain both the ETS domain and the CID 
(Fig. 3.4a-b and Table 3.3) as mapped in ETV4 (Fig. 3.3), were very similar with 
a root mean square deviation (RMSD) of 0.16 Å for alignment of their ETS 
domains. The CID includes an α-helix, termed H4, that packs on one face of the 
ETS domain. In ETV4, Ala426 and Leu430 in H4 lie in a hydrophobic groove 
along the ETS domain in proximity to Trp344 from H1, Ile407 from the loop 
between H3 and S3, and Phe420 from S4 (Fig. 3.4c). Homologous residues had 
similar interactions in ETV1. Replacing Leu430 with an alanine resulted in a 
reduction in autoinhibition (activation in DNA binding), whereas mutation to 
methionine, the homologous amino acid in ETV1 and ETV5, had no effect on 
DNA binding (Fig. 3.4d). These structural and functional data demonstrated that 
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the CID inhibits DNA binding through intramolecular contacts between H4 and 
the ETS domain, mediated in part by a leucine or methionine in H4. 
Based on the crystal structures of CID-inhibited ETV1 and ETV4, we 
noted that the uninhibited, minimal DBD fragments used for demonstrating 
autoinhibition in ETV1, ETV4, and ETV5 (Fig. 3.1) were predicted to have a 
shorter or possibly unfolded helix H4. As with ETV4 (Fig. 3.3a), loss of these 
homologous residues in ETV1 and ETV5 also activated DNA binding (Fig. 3.5a). 
Therefore, an intact and full-length H4 is a necessary and conserved feature of 
the CID.  
To understand the structural nature of the residues mapped to H4 within 
the context of uninhibited ETV1, ETV4, and ETV5, we attempted to crystalize 
these fragments with success for ETV5 (1.8 Å resolution; Table 3.3). Despite the 
deletion of amino acids mapped to the intact H4, the α-helix is retained, albeit 
truncated. However, the shorter H4 is rotated ~ 60° away from the ETS domain 
relative to the position of the full-length H4 in ETV1 and ETV4 (Fig. 3.5b). This 
alternate position is accommodated in the crystal by intermolecular contacts 
between the truncated H4 and the ETS domain of a neighboring molecule (Fig. 
3.6). With H4 in this alternate position, Met457 is unable to form the 
intramolecular inhibitory contacts with the ETS domain observed for the 
homologous Met424 and Leu430 in the CID-inhibited structures of ETV1 and 
ETV4, respectively, potentially explaining the loss of autoinhibition of this 
fragment (compare Fig. 3.4b and 3.5b). In conclusion, the relief of autoinhibition 
by the partial truncation of H4 and by disruption of an intramolecular contact 
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between H4 and the ETS domain demonstrated the role of H4 in autoinhibition. 
In addition, while the alternate position of truncated H4 is potentially a 
consequence of crystallization, we propose that this repositioning indicates an 
intrinsic mobility of the CID, an idea pursued further by NMR studies below. 
 
A CID connection to the DNA-recognition helix H3  
mediates autoinhibition 
To further our structural studies of ETV1/4/5, we compared our crystal 
structures of the uninhibited ETV5 with a truncated H4 to that of the CID-inhibited 
ETV1 and ETV4 with a full-length H4. In comparison to the highly similar CID-
inhibited ETV1 and ETV4 structures (RMSD of 0.16 Å), the ETS domain from 
uninhibited ETV5 was distinct with RMSD values of 0.79 Å and 0.72 Å when 
aligned to ETV1 and ETV4, respectively (Fig. 3.7a). Closer examination of 
subsections of the ETS domain revealed that the differences between uninhibited 
and CID-inhibited structures were most pronounced around the DNA-recognition 
helix H3, as well as β-strands 3 and 4. Visually, the backbone of the C-terminal 
half of the DNA-recognition helix H3 is shifted about 2 Å between the inhibited 
and uninhibited structures, relative to the rest of the ETS domain (Fig. 3.5c). 
Further comparison with the structure of ETV4 in complex with DNA27 
demonstrated that in the DNA-bound form, H3 of ETV4 is also shifted to a similar 
position as observed for uninhibited ETV5 (Fig. 3.5c and Fig. 3.7c). We 
speculate that in the ETV1/4/5 subfamily, the active state of a DNA-bound ETS 
domain requires this shift of H3 and, thus, matches the conformation we 
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observed in the uninhibited species.  
Having observed the activating phenotype of the ETV4 mutant L430A 
(Fig. 3.4d) and the variable positioning of the DNA-recognition helix H3 in our 
crystal structures (Fig. 3.5c), we hypothesized that Leu430 inhibits the ETS 
domain by modulating H3 positioning through an interaction with Ile407 in the 
H3-S3 loop. We tested this postulate by mutating Ile407 and Leu430 each to 
alanine separately and in combination. The ETV4 mutant I407A had an almost 5-
fold reduction in DNA-binding affinity compared to the wild-type protein, but 
importantly, this mutation also abrogated the activating nature of L430A in the 
double mutant I407A/L430A (Fig. 3.5d). We conclude that the Leu430-Ile407 
interaction is required for CID-mediated autoinhibition and propose that CID-
mediated autoinhibition functions by restricting the accessible conformations of 
H3.  
 
Dynamic features of CID autoinhibition mechanism  
detected by NMR 
To further investigate the mechanism of autoinhibition, we utilized NMR 
spectroscopy to compare uninhibited and CID-inhibited species. 15N-HSQC 
spectra were analyzed for two ETV4 fragments, which displayed the same 
affinities for DNA as the uninhibited and CID-inhibited species discussed above 
(Fig. 3.8a-c). Based on mainchain chemical shifts, the two proteins in solution 
contained truncated or full-length H4, as observed by crystallography. Spectral 
differences demonstrated that amides in the loop between H1 and S1, the C-
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terminal end of H3, and H4 were most affected by the presence of the full-length 
H4 (Fig. 3.8d,e). The amino acids in H3 that were perturbed match closely to 
those undergoing the backbone realignment observed in the comparison of the 
crystal structures of CID-inhibited ETV1 and ETV4 versus uninhibited ETV5. 
Thus, the interaction between H4 and the ETS domain, as well as the H4-
dependent perturbations of H3, observed in the crystal structures are also 
retained in solution. 
In additional NMR experiments, the dynamics of uninhibited ETV4 were 
analyzed using amide hydrogen exchange (HX). Residues within H1, H2 and the 
β-sheet displayed relatively large protection factors (>104), indicating that they 
form the stable core of the ETS domain (Fig. 3.8f,g). In contrast, residues 
preceding the ETS domain and in loop regions had lower protection factors, 
which is indicative of conformational flexibility. In addition, many residues, and 
especially those in H3 and H4, exhibited HX that was too fast to detect by 1H/2H 
exchange yet too slow to be measured by 1H/1H magnetization transfer. This 
implies that the protection factors of these residues are also low, in the 
approximate range of 50 to 1000. Thus, the DNA-recognition α-helix H3, and the 
inhibitory CID helix H4 are conformationally dynamic and readily sample partially 
unfolded states detectable by HX. Similar behavior is observed with the DNA-
recognition and inhibitory helices of ETS18,14 and ETV612,13.  We conclude that 
the CID autoinhibitory mechanism requires an equilibrium involving dynamic 
interactions between helices H4 and H3. 
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An intrinsically disordered NID connects to CID and  
helix H3 
Attempts to characterize the NID structurally by crystallization of larger 
fragments of ETV4 were unsuccessful, potentially reflecting the predicted 
disordered nature of the NID (Fig. 3.2d). Consistent with this prediction, the 15N-
HSQC spectrum of the isolated ETV4 NID, amino acids 165-336, displayed 
limited 1HN chemical shift dispersion, (Fig. 3.9a). An analysis of the assigned 
mainchain 1H, 13C, and 15N chemical shifts confirmed that the NID predominantly 
samples random coil conformations (Fig. 3.9b). Circular dichroism added 
additional evidence for the overall disordered character of the NID (Fig. 3.10).  
Many IDRs, while disordered in isolation, take on a more structured 
character in the presence of a binding partner through a coupled “folding and 
binding” mechanism28. Therefore, we asked whether the NID is still disordered 
while making inhibitory contacts with the ETS domain. Using intein technology, 
we ligated the 15N-labeled NID, residues 165-336, to an unlabeled ETV4 
fragment spanning the ETS domain and the CID, amino acids 337-436. The NID 
spectrum retained limited 1HN chemical shift dispersion, indicating the lack of any 
persistent induced secondary structure when covalently linked "in cis" to a 
fragment spanning the ETS domain and CID (Fig. 3.9a,c). This comparison 
indicates that the NID remains disordered while transiently interacting with the 
ETS domain and/or CID of ETV4. 
With a better understanding of the separated NID and the CID, we next 
investigated the basis of cooperative inhibition imparted by these two inhibitory 
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domains. To map the possible interaction of the NID with the ETS domain and 
the CID of ETV4, we compared the 15N-HSQC spectra of an ETV4 fragment 
containing the ETS domain and the CID only, amino acids 337-436, with an 
ETV4 fragment also containing the NID, amino acids 165-436 (Fig. 3.11a). As 
described above, for spectral simplification, an unlabeled NID was added by 
intein technology to a 15N-labeled fragment containing the ETS domain and CID. 
In addition to the expected changes at the N-terminus of H1, the ligated NID 
weakly perturbed amides in H2, the C-terminal region of H3 and the surface-
exposed face of the CID (Fig. 3.11b,c). These chemical shift perturbations 
indicate that the NID directly or indirectly affects the structural environment of 
amides in these regions of the ETS domain and the CID.  
To further characterize the NID regions that are responsible for 
autoinhibition, we investigated the activities of ETV4 variants bearing acetylated 
lysines. Multiple lysine acetylation sites have been described for ETV429,30 with 
some reported to activate DNA binding31. Two known sites of acetylation, Lys226 
and Lys260, reside within the NID. Acetylation of either Lys226 or Lys260, 
independently, resulted in a decrease of DNA binding autoinhibition by 2.8 or 1.6 
fold, respectively (Fig. 3.12). We propose that acetylation of these lysines 
relieves autoinhibition by disrupting intramolecular interactions between the NID 
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Discussion 
Cooperative autoinhibition of DNA binding 
Here, we have observed that the ETV1/4/5 subfamily of ETS factors 
include regions N- and C-terminal to the ETS domain that act cooperatively to 
inhibit DNA binding. Based on the following evidence, we propose that CID-
mediated inhibition functions by restricting the binding-competent conformation of 
the DNA-recognition helix H3. The C-terminal region of the DNA-recognition helix 
H3 adopts a position in uninhibited ETV5 that is distinct from that in CID-inhibited 
ETV1 and ETV4, but is very similar to that of the DNA-bound form of ETV427. 
NMR-spectroscopy confirms that the CID influences H3, consistent with a model 
of conformationally-induced inhibition. Additionally, Leu430 and Ile407 are 
required for CID-mediated inhibition and establish a direct link between H4 and 
H3 for mediating inhibition. 
In contrast to the structured CID, the NID is predominantly intrinsically 
disordered and interacts only transiently with the ETS domain and CID. Most 
notably, these interactions, which could be direct or propagated through the 
protein, localize on the C-terminal region of H3, as well as on H4. Therefore, the 
NID may cooperate directly with the CID by reinforcing its inhibitory positioning, 
and/or indirectly through interaction with helix H3. Acetylation of the NID 
activates DNA binding, likely through disruption of the intramolecular interactions 
between the NID and the ETS domain and/or the CID. In conclusion, we submit 
that apo-forms of ETV1, ETV4, and ETV5 are in a dynamic equilibrium between 
conformations of H3 that are competent and incompetent for binding to DNA 
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(Fig. 3.13a). Potential mechanisms for the relief of autoinhibition for these 
proteins include co-localization with the acetyltransferase p30029, alternative 
splicing or use of a translational start site that would remove the NID4,32,33, and 
protein-protein interactions that would disrupt or reinforce the intramolecular 
interactions between the NID and/or the CID and the ETS domain16,31.  
 
Autoinhibition in ETS family of transcription factors 
The characterization of autoinhibition in the ETV1/4/5 subfamily adds to 
the diversity of structural elements utilized in inhibiting DNA binding by ETS 
factors (Fig. 3.13b). Despite this diversity, common themes of autoinhibition in 
ETS factors include the low stability of the inhibitory helices and integration of 
structured and IDR inhibitory elements. 
In the cases of ETS1 and ETV6, inhibitory α-helices unfold upon binding 
DNA13,34, whereas DNA-bound structures of ETV1/4/5 subfamily members27 
demonstrate that H4 remains folded. However, in uninhibited ETV5, the 
truncated α-helix H4 shows a drastic repositioning away from the ETS domain, 
forming intermolecular interactions with a neighboring molecule within the crystal 
lattice. Along with the low HX protection factors of H4, these structural data 
suggested that H4 is flexible and our functional data demonstrated a connection 
between H3 and H4 influences DNA binding. 
Regulation of internal molecular motion is important for transcription factor 
binding to specific DNA sequences35 and a dynamic, active state has been 
proposed as a requirement for transcription factor recognition of cognate DNA 
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sites36. The inhibitory sequences of ETS1, ETV6, and ERG have been shown to 
dampen the internal dynamics of the ETS domain8,11,12. Therefore, despite the 
structural divergence of ETS inhibitory elements, they may share a convergent 
mechanism of restricting the internal dynamics of the ETS domain. The 
conformational changes in inhibited versus uninhibited ETV1/4/5 factors 
suggests that the dampening of motions may also contribute to autoinhibition in 
this subfamily, but additional experiments are required to confirm this hypothesis.  
The modulation of autoinhibition by both structured and disordered regions 
is a shared feature all structurally-characterized ETS factors8,10,11. The 
cooperation of structured and disordered inhibitory elements in the ETV1/4/5 
subfamily factors is most similar to that of ETS1. Four α-helices flanking the ETS 
domain of ETS1 provide a slight level of inhibition26, and this autoinhibition is 
reinforced by an IDR, termed the serine-rich region (SRR)8,14. As is the case for 
the proposed interaction between the NID and the ETS domain/CID of ETV4, the 
dynamic SRR also interacts transiently with both the flanking inhibitory helices of 
ETS1 and its ETS domain. Furthermore, tyrosine and phenylalanine residues, 
amino acids that are usually depleted within IDRs37, are present in the SRR of 
ETS138 and in the NID of ETV1, ETV4, and ETV5. In ETS1, these aromatic 
residues reside in a repeating pattern of Ser-(Tyr/Phe)-Asp repeats that is not 
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Autoinhibition via IDRs as a molecular target 
In light of the challenge of designing an inhibitor targeted at a conserved 
DNA interface, the presence of heterogeneous inhibitory elements amongst ETS 
factors provides some hope for new strategies. IDRs often form intermolecular 
interactions with structured domains, and progress has been made in targeting 
inhibitors to the structured components of these interactions39,40. However, 
targeting the IDR directly is difficult using structure-based or rational inhibitor 
design due to their conformational heterogeneity and a lack of binding pockets 
suitable for energetically favorable interactions with a small molecule inhibitor41. 
Nevertheless, recent reports have described high-throughput screening 
approaches that successfully identified inhibitors that modulate protein activity 
through direct interaction with IDRs. Examples include the transcription factor c-
MYC, the protein tyrosine phosphatase PTP1B, the TAF2 subunit of the general 
transcription factor TFIID, and ETV142-45. Although the exact epitope(s) on ETV1 
targeted by the inhibitor was not identified structurally, the small molecule 
inhibited cell migration in a mechanism dependent on the acetylation of Lys33 
and Lys116. These lysines are distinct from ETV4 Lys226 and Lys260, which are 
involved in ETV4 autoinhibition, but also reside within IDRs. These examples of 
small molecule – IDR interactions demonstrate the feasibility of targeting IDRs 
and their function. The use of a small molecule to inhibit DNA binding by 
reinforcing the interaction between the ETS domain and the disordered NID of 
ETV1/4/5 subfamily proteins would be a novel molecular therapeutic approach.  
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Methods 
Expression plasmids  
 Human ETV1, ETV4, ETV5, ERG, and FLI1 cDNAs corresponding to full-
length or truncated proteins were cloned into the bacterial expression vector 
pET28 (Novagen) using standard sequence- and ligation-independent cloning 
strategies46. Point mutations were introduced into the ETV4 plasmid using the 
QuikChange site-directed mutagenesis protocol (Stratagene). For acetylation 
studies, codons encoding Lys226 or Lys260 in the full-length ETV4 gene were 
mutated to an amber codon (UAG), and the natural amber stop codon was 
mutated to an opal codon (UGA). Mutated ETV4 cDNA was then cloned from the 
pET28 plasmid into a pCDF plasmid (kind gift from Dr. Jason Chin) for 
expression47. 
 
Expression and purification of proteins  
 All proteins were produced in Escherichia coli (lDE3) cells. Uninhibited 
ETS factor DNA-binding domains and the ETV1/4/5 fragments not containing the 
NID were efficiently expressed into the soluble fraction. Cultures of 1 L Luria 
broth (LB) were grown at 37 °C to OD600 ~ 0.7 – 0.9, induced with 1 mM 
isopropyl-b-D-thiogalactopyranoside (IPTG), and grown at 30 °C for ~ 3 hours. 
To produce isotopically enriched proteins, expression was carried out using M9 
minimal media supplemented with 3 g/L (13C6, 99%)-D-glucose and/or 1 g/L (15N, 
99%)-NH4Cl.  
Harvested cells were resuspended in 25 mM Tris pH 7.9, 1 M NaCl, 5 mM 
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imidazole, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM 2-
mercaptoethanol (BME), and 1 mM phenylmethanesulfonylfluoride (PMSF). Cells 
were lysed by sonication and centrifuged at 40k rpm in a 45 Ti rotor (Beckman) 
for at least 30 minutes at 4 °C. After centrifugation, the soluble supernatants 
were loaded onto a Ni2+ affinity column (GE Biosciences) and eluted over a 5 – 
500 mM imidazole gradient. Fractions containing purified protein were pooled, 
combined with ~ 1 U thrombin / mg of purified protein, and dialyzed overnight at 4 
°C into 25 mM Tris pH 7.9, 10% glycerol (v:v), 1 mM EDTA, 50 mM KCl, and 1 
mM dithiothreitol (DTT). After centrifugation at 40k rpm for 30 minutes at 4 °C, 
the soluble fraction was loaded onto a SP-sepharose cation exchange column 
(GE Biosciences) and eluted over a 50 – 1000 mM KCl gradient. Fractions 
containing the ETS proteins were loaded onto a Superdex 75 gel filtration column 
(GE Biosciences) in 25 mM Tris pH 7.9, 10% glycerol (v:v), 1 mM EDTA, 300 mM 
KCl and 1 mM DTT. Eluted fractions were analyzed by SDS-PAGE. The final, 
purified protein was then concentrated on a 10-kDa molecular weight cut-off 
(MWCO) Centricon device, snap-frozen with liquid nitrogen, and stored at -80 °C 
in single-use aliquots for subsequent EMSA studies.  
Full-length ETS factors and ETV4 truncations containing the NID generally 
expressed more efficiently in the insoluble fraction using an “auto-induction” 
protocol48. Briefly, bacteria in 250 mL of autoinduction media were grown in 4 L 
flasks at 37 °C to an OD600 ~ 0.6 – 1. The temperature was then reduced to 30 
°C and cultures were grown for another ~ 12 – 24 hours. Final OD600 values were 
typically ~ 6 – 12, indicating robust autoinduction. Harvested cells were 
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resuspended as described above, sonicated, and centrifuged at 15k rpm in a JA-
17 rotor (Beckman) for 15 minutes at 4 °C. The soluble fraction was discarded 
and this procedure was repeated with the pellet / insoluble fraction twice more to 
rinse the inclusion bodies. The final insoluble fraction was resuspended with 25 
mM Tris pH 7.9, 1 M NaCl, 0.1 mM EDTA, 5 mM imidazole, 2 mM BME, 1 mM 
PMSF, and 6 M urea. After sonication and incubation for ~ 1 hour at 4 °C, the 
sample was centrifuged for 40k rpm for at least 30 minutes at 4 °C. The soluble 
fraction was loaded onto a Ni2+ affinity column (GE Biosciences) and refolded by 
immediately switching to a buffer with the same components as above, except 
lacking urea. After elution with 5 – 500 mM imidazole, the remaining purification 
steps using ion-exchange and size-exclusion chromatography were performed as 
described above. However, a Q-sepharose anion-exchange column was used 
instead of a SP-sepharose cation-exchange column due to differing isoelectric 
points of the desired proteins. 
Acetylated full-length ETV4 proteins were expressed according to a 
published protocol47. Briefly, expression was induced with IPTG, as described 
above, but in the presence of 10 mM acetyllysine and 20 mM nicotinamide and a 
plasmid encoding an amber tRNA that has been mutated in order to be charged 
with acetyllysine. Acetylated proteins were purified as outlined above for 
unacetylated full-length ETV4.  
ETV4 proteins prepared for NMR spectroscopy were purified using 
protocols slightly different from above. Harvested cells were resuspended in 50 
mM Na2HPO4, 500 mM NaCl, 10 mM imidazole, 6M guanidinium HCl, pH 7.4, 
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and lysed by at least one round of freeze/thaw, followed by passage 5 times 
through an EmulsiFlex-C5 homogenizer at 10 kPa, and finally, 15 minutes of 
sonication. The cell lysate was spun down by centrifuging at 25,000 x g for 1 
hour at 4 °C. The supernatant containing ETV4 was then loaded onto Ni2+ affinity 
column (GE Biosciences), washed with 30 mM imidazole and eluted with 1000 
mM imidazole and 6 M guanidinium HCl. Eluted fractions containing the desired 
protein were dialyzed against 3 L of refolding buffer (50 mM Na2HPO4, 1 M NaCl, 
2 mM DTT and 1 mM EDTA, pH 7.5) at 4 °C overnight. The His6-tag of the 
refolded proteins was cleaved by adding 1 U of thrombin/mg or TEV-protease at 
a TEV/protein ratio of 1/200 (w/w). The mixture was loaded onto another Ni2+ 
affinity column, and the flow-through containing the tag-free ETV4 fragment was 
concentrated using a 3 kDa MWCO Centricon device to 2 mL. Size exclusion 
chromatography with Superdex 75 was used for a last purification step. Eluted 
fractions were assessed using SDS-PAGE and those containing the purified 
protein were pooled and dialyzed against NMR sample buffer (20 mM Na2HPO4, 
200 – 1000 mM NaCl, 2 mM DTT, 0.1 mM EDTA, pH 6.5).  
Protein concentrations were determined by measuring the absorbance at 
280 nm using predicted ε280 values, or at 595 nm after mixing 20 µL of protein 
with 1 mL of Bio-Rad Protein Assay Dye Reagent (diluted 1:5 in deionized water) 
and comparing to a bovine serum albumin standard curve. Molecular weights for 
each ETS protein were predicted using the Peptide Property Calculator 
(Northwestern).  
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Expressed protein ligation and purification 
 The DNA sequence encoding ETV4 ETS domain and CID, amino acids 
337-436, was sub-cloned into bacterial expression vector pEM5B (kind gift from 
Dr. Pierre Barraud, Université Paris Descartes) between XhoI and BamHI 
restriction sites. This enabled the addition of the required cysteine and TEV 
cleavage site (ENLYFQC) preceding the ETS domain, as described for the 
segmental labeling and expressed protein ligation protocol49. The protein 
construct was expressed in M9 media, purified under denaturing conditions, and 
refolded as described above. Protein was concentrated to 0.3 mM as measured 
by absorbance at 280 nm (predicted ε280 57995 M-1cm-1) and stored in the 
inactive reaction buffer (50 mM HEPES, 200 mM NaCl, 0.1 mM TCEP, pH 7).   
 The DNA sequence encoding ETV4 NID, amino acids 165-336, was sub-
cloned into pEM9B (kind gift from Dr. Pierre Barraud) between NdeI and SapI 
restriction sites. The pEM9B expression vector also encodes a C-terminal Mxe 
GyrA intein. Nine additional amino acids (GGGHM preceding and GSSC 
following the NID) were introduced as a result of cloning and to enable protein 
ligation. The protein construct was expressed in LB media, cells were harvested 
and resuspended in native buffer (50 mM Na2HPO4, 500 mM NaCl, 10 mM 
imidazole, pH 7.4), and lysed by cell homogenization and sonication, as 
described above. The supernatant containing the desired protein was purified 
under native conditions first by loading onto the Ni2+ affinity column, washed by 
30 mM imidazole and eluted with 1000 mM imidazole. The protein was 
concentrated to 0.5 mM, as measured by absorbance at 280 nm (predicted ε280 
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63760 M-1cm-1), and stored in the inactive reaction buffer (50 mM HEPES, 200 
mM NaCl, 0.1 mM TCEP, pH 7).  
 Purified protein samples containing 15N-labeled ETV4 ETS domain and 
CID, amino acids 337-436, and unlabeled ETV4 NID, amino acids 165-336, were 
mixed in a 1:2 molar ratio. The reaction was activated by adding 100 mM 2-
mercaptoethanesulfonate (MESNA) and TEV-protease at a TEV/protein ratio of 
1/200 (w/w). The reaction mixture was incubated at 16 °C for 5 days. Time points 
were collected and analyzed on SDS-PAGE to monitor the ligation efficiency. 
TEV-protease cleaved products and intein self-cleaved products were purified on 
a chitin column equilibrated with 50 mM HEPES, 200 mM NaCl, pH 7. The flow-
through of the chitin column containing the ligated product was purified on either 
ion-exchange chromatography (Mono Q) equilibrated with 50 mM HEPES pH 7 
and eluted with 0 – 1000 mM NaCl gradient, and/or size exclusion 
chromatography (Superdex 75) equilibrated with NMR sample buffer. Fractions 
containing the final product were verified by SDS-PAGE and MALDI-ToF mass 
spectrometry on a Voyager-DE STR (Applied Biosystems) with a sinapinic acid 
matrix. The final product was dialyzed against NMR buffer (20 mM Na2HPO4, 200 
mM NaCl, 2 mM DTT, 0.1 mM EDTA, pH 6.5). For the ligation reaction using 15N-
labeled ETV4 NID, amino acids 165-336, and unlabeled ETV4 ETS domain and 
CID, amino acids 337-436, equal molar ratio were mixed (100 µM) to minimize 
aggregation due to highly concentrated ETV4 337-436. The reaction was initiated 
and the final product was purified and confirmed, as described above.  
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Electrophoretic mobility shift assays (EMSAs) 
 DNA-binding assays of ETS factors utilized a duplexed 27-bp 
oligonucleotide with a consensus ETS binding site: 5’-
TCGACGGCCAAGCCGGAAGTGAGTGCC-3’ (arbitrarily assigned as “top” 
strand) and 5’-TCGAGGCACTCACTTCCGGCTTGGCCG-3’ ("bottom" strand). 
Boldface GGAA indicates the consensus ETS binding site motif. Each of these 
oligonucleotides, at 2 µM as measured by absorbance at 260 nM on a NanoDrop 
1000 (Thermo Scientific), were labeled with [g-32P] ATP using T4 polynucleotide 
kinase at 37 °C for ~ 30 – 60 minutes. After purification over a Bio-Spin 6 
chromatography column (Bio-Rad), the oligonucleotides were incubated at 100 
°C for ~ 5 minutes, and then cooled to room temperature over 1 – 2 hours. The 
DNA for EMSAs was diluted to 1 x 10-12 M and held constant, whereas protein 
concentrations ranged ~ 6 orders of magnitude with the exact concentrations 
dependent on the KD of particular protein fragments. Protein concentrations were 
determined after thawing each aliquot of protein, using the Protein Assay Dye 
Reagent. Equivalent starting amounts (0.2 mg) of each protein utilized on a given 
day were run on an SDS-PAGE gel to confirm their relative concentrations. The 
binding reactions were incubated for 45 minutes at room temperature in a buffer 
containing 25 mM Tris pH 7.9, 0.1 mM EDTA, 60 mM KCl, 6 mM MgCl2, 200 
mg/mL BSA, 10 mM DTT, 2.5 ng/mL poly(dIdC), and 10% (v:v) glycerol, and then 
resolved on an 8% (w:v) native polyacrylamide gel at room temperature. The 32P-
labeled DNA was quantified on dried gels by phosphorimaging on a Typhoon Trio 
Variable Mode Imager (Amersham Biosciences). Equilibrium dissociation 
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constants (KD) were determined by nonlinear least squares fitting of the total 
protein concentration [P]t versus the fraction of DNA bound ([PD]/[D]t) to the 
equation [PD]/[D]t = 1/[1 + KD/[P]t)] using Kaleidagraph (v. 3.51; Synergy 
Software). Due to the low concentration of total DNA, [D]t, in all reactions, the 
total protein concentration is a valid approximation of the free, unbound protein 
concentration. Reported KD values represent the mean of at least three 
independent experiments and the standard error of the mean. 
 
Partial proteolysis 
 For tryptic digestion studies, 20 mL ETV4 (FL) at 20 mM was incubated 
with 1.5 – 450 ng of trypsin (Sigma) in a buffer containing 25 mM Tris pH 7.9, 10 
mM CaCl2, and 1 mM DTT. After 2 minutes of incubation, the reaction was 
quenched with 1 % (v:v) acetic acid (final volume). The resulting samples were 
analyzed by SDS PAGE and ESI-MS (total mixture analyzed), and used for 
EMSA studies. 
 
Crystallization and structure determination 
 Purified proteins were dialyzed overnight in 10 mM Tris pH 7.9 and 50 mM 
NaCl, and then concentrated to 5 mg/mL. Crystals were grown by vapor diffusion 
in sitting drops of 2:1 protein:reservoir (v:v). CID-inhibited ETV1, amino acids 
332-435, was crystallized against a reservoir of 30% (w:v) PEG 5000 
monomethyl ether, 0.1 M MES sodium salt, and 0.2 M ammonium sulfate at pH 
6.5 and 20 °C. CID-Inhibited ETV4, amino acids 337-441, was crystallized 
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against a reservoir of 1 M di-ammonium phosphate and 0.1 M sodium acetate at 
pH 4.5 and 20 °C. Uninhibited ETV5, amino acids 364-457, was crystallized 
against a reservoir of 0.2 M di-ammonium pH 5.0 and 20% PEG 3350 at pH 5.0 
and 4 °C. 
 Crystals were immersed briefly in mother liquor containing 20% glycerol, 
and then cryocooled by plunging into liquid nitrogen. Diffraction data were 
collected on a Q315 CCD using Stanford Synchrotron Radiation Lightsource 
(SSRL) beamline 7-1 with X-rays at 1.0000 Å (ETV1 and ETV4) or 1.1271 Å 
(ETV5). The resulting data were integrated and scaled using HKL200050. Phases 
were determined by molecular replacement with Phaser-MR51 using the ETS 
domain of ETS1 (1MD0.pdb) as a search model. Models were built with COOT52 
and refined with PHENIX53. PyMOL (Schrödinger, LLC) was used to render 
molecular structure figures. 
 Model geometries were analyzed by MolProbity54 within PHENIX. For 
ETV1, 87.5% of residues have favorable backbone dihedrals and 12.5% fall into 
allowed regions. Residues 332-333 and 435 were not visible in the electron 
density. For ETV4, 91.8% of residues have favorable backbone dihedrals and 
8.2% of residues fall into allowed regions. Residues 337-339 and 337-441 were 
not visible in the electron density. For ETV5, 87.7% of residues have favorable 
backbone dihedrals and 12.3% of residues fall into allowed regions. Residues 
364-365 were not visible in the electron density. 
 The coordinate files have been deposited to the RCSB under accession 
codes 5ILS, 5ILU, and 5ILV. 
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Circular dichroism spectroscopy 
 Frozen ETV4 NID, amino acids 165-336, aliquots were thawed, dialyzed 
overnight into 20 mM Na2HPO4, 50 mM NaCl, pH 7.9, and diluted to 25 mM 
concentration. CD spectra were recorded at 4 °C over the wavelength range of 
190-260 nm with a 1 nm wavelength step. A baseline reference, consisting of 
buffer only, was subtracted from the CD spectra. Three scans were collected in 
series and averaged after visually verifying their consistency. Data were 
converted to molar ellipticity as described55. 
 
NMR spectroscopy  
 NMR data were recorded at 25 °C on cryoprobe-equipped 500, 600, and 
850 MHz Bruker Avance III spectrometers. Proteins were in NMR sample buffer 
(plus 10% lock D2O) with 1 M NaCl for spectral assignments and with 200 mM 
NaCl for all other experiments. The elevated ionic strength reduced slow 
aggregation over long-term measurements. Data were processed and analyzed 
using NMRpipe56 and Sparky57. Signals from mainchain and sidechain 1H, 13C, 
and 15N nuclei were assigned by standard multidimensional heteronuclear 
correlation experiments, including 15N-HSQC, HNCO, HN(CA)CO, 
CBCA(CO)NH, and HNCACB58. Amide 1H/2H, after transfer into ~ 99% D2O NMR 
sample buffer via a spin column, and CLEANEX-PM 1H/1H hydrogen exchange 
(HX) measurements were recorded using 850 MHz NMR spectrometer and 
analyzed as described previously12,59. 
 
 







Figure 3.1 Autoinhibition in the ERG and ETV1/4/5 subfamilies.  (a) Schematic of 
full-length protein, FL, and nearly minimal DNA-binding domain, DBD, for ETV4. 
Based on the sequences of all ETS factors, the conserved ETS domain, ED, is 
noted in red. (b, c) Representative examples of EMSA gels and binding 
isotherms for ETV4 FL or DBD with a double-stranded DNA duplex containing a 
core ETS binding site, see methods for details. (d) Fold inhibition of ERG, FLI1, 
ETV1, ETV4, and ETV5, calculated as KD (FL or DBD) / KD (DBD). ETS18,# and 
ETV610,$ data are included for comparison. Mean and standard error of the mean 
from at least three replicates are plotted; “*” indicates p < 0.01. See Table 3.1 for 
KD values and number of replicates for each protein. (e) KD values of FL versus 
DBD for each of the ETS factors tested. The dotted line on the diagonal 





















































































a Mean and standard error of the mean are given for KD and fold-inhibition values. 
b The DBD is set as uninhibited and used as a reference for calculating fold inhibition as 
KD (FL or DBD) / KD (DBD). 
c The p-values were calculated using a two-tailed heteroscedastic t-test and compare the 
DBD and FL fragments for each ETS factor. 
d Data included for comparison from reference8. 







Table 3.1  
Equilibrium dissociation constants and fold-inhibition values for ETS 
transcription factors 
 
     ETS 
Factor       Fragment KD (x 10
-11 M)a Fold Inhibitiona,b pc n 
ERG DBD (307-400) 40 ± 10 1.0 ± 0.5 - 3 
FL (1-479) 94 ± 9 2.3 ± 0.9 0.05 3 
      
FLI1 DBD (277-370) 26 ± 8 1.0 ± 0.4 - 7 
FL (1-452)  70 ± 20 3 ± 1 0.1 3 
      
ETV1 DBD (332-425) 5.4 ± 1.0 1.0 ± 0.3  
6 
FL (1-479) 110 ± 20 21 ± 6 0.0006 10 
      
ETV4 DBD (337-430) 6.1 ± 0.6 1.0 ± 0.1 - 25 
FL (1-484) 83 ± 8 14 ± 2 3 x 10-7 35 
      
ETV5 DBD (364 - 457) 3.6 ± 0.4 1.0 ± 0.2 - 4 
FL (1-510) 140 ± 30 39 ± 9 0.003 8 
      
ETS1d DBD 1.1 ± 0.1 1.0 ± 0.1 - 3 
FL 32 ± 4 29 ± 4 0.002 3 
      
ETV6e DBD 280 ± 40 1.0 ± 0.2 - 4 
FL 2,800 ± 400 10 ± 2 0.004 4 







Figure 3.2 ETV4 165-484 is a trypsin-resistant fragment. (a) SDS-PAGE gel of 
partial trypsin proteolysis of ETV4. The left-most lane contains protein molecular 
weight standards, and the next seven lanes show products from digestion with 
450, 150, 45, 15, 4.5, 1.5, and 0 ng of trypsin. A representative example of three 
independent experiments is displayed. (b) Electrophoretic mobility shift assay 
with tryptic fragments from (a). The far right lane is a DNA-only control. (c) 
Schematic of ETV4 full-length (FL) and tryptic fragments retaining the ETS 
domain as identified by electrospray ionization mass spectrometry (ESI-MS). The 
predominant DNA-binding tryptic fragments are arbitrarily named T1, T2, and T3. 
The black bar refers to an N-terminal His6 tag encoded by the pET28 vector and 
the vertical lines mark potential trypsin digestion sites as predicted by ExPASY 
Peptide Cutter. The ETS domain (ED) is noted in red, and N-terminal inhibitory 
domain (NID) and C-terminal inhibitory domain (CID), as identified for ETV4 (Fig. 
3.3), are noted in cyan. (d) Predicted disorder values are plotted over the full 
length of ETV1 (top), ETV4 (middle), and ETV5 (bottom). These values, 
calculated using Predictor of Naturally Disordered Regions (PONDR) VL360, 
range from 0 (likely ordered) to 1 (likely disordered). Potential trypsin digestion 
sites are denoted by “X”. Red lines refer to residues that span the ETS domain 
(ED), cyan lines in ETV4 refer to the NID and CID as identified for ETV4 (Fig. 
3.3). 
 








Figure 3.3 NID and CID cooperate to inhibit ETV4 DNA binding.  (a) Fold 
inhibition of the ETV4 fragments with mean and standard error of the mean 
displayed. Fold inhibition calculated as KD (fragment) / KD (DBD). “*” Indicates p < 
0.01. See Table 3.2 for KD values and number of replicates for each protein. (b) 
DDG = RT ln (KD ETV4 inhibited fragment / KD ETV4 337-430) measured for 
fragments containing the NID, amino acids 165-430, the CID, 337-484, or both, 
165-484. The dotted line indicates the sum of the DDG values for 165-430 and 
337-484. (c) Schematic of ETV4 autoinhibition depicting cooperative inhibitory 























































a Mean and standard error of the mean are given for KD and fold-inhibition values. 
b ETV4 (DBD) 337-430, the uninhibited fragment, was used as a reference for 
calculating fold inhibition as KD (fragment or full length) / KD (ETV4 337-430). 




Table 3.2  
Equilibrium dissociation constants and fold-inhibition values for ETV4 
fragments 
     ETV4 Fragment KD (x10-11 M)a Fold Inhibitiona,b n pc 
337-430 (DBD) 6.1 ± 0.6 1.0 ± 0.1 25 - 
337-436 12 ± 2 1.9 ± 0.3 23 0.009 
337-484 11 ± 2 1.7 ± 0.4 4 0.04 
165-430 12.5 ± 0.3 2.1 ± 0.2 3 0.03 
165-484 66 ± 9 11 ± 2 18 3 x 10-7 
1-484 (FL)  83 ± 8 14 ± 2 35 4 x 10-7 
     








Figure 3.4 CID inhibits DNA binding through hydrophobic contacts between α-
helix H4 and the ETS domain. (a) Schematic of ETS domain, H1-H3 and S1-S4, 
and α-helix H4 of ETV1, ETV4, and ETV5. ETS domain, red; inhibitory elements, 
cyan; α-helices, cylinders; β-strands, arrows. (b) Cartoon representations of the 
aligned structures for the ETS domain and CID of ETV1 and ETV4, amino acids 
332-435 and 337-441, respectively. Displayed in stick format are Ala426 and 
Leu430 from α-helix H4 in ETV4, and the analogous amino acids Ala420/Met424 
from ETV1, as well as the conserved amino acids in the ETS domain that form a 
hydrophobic cluster. Numbering for amino acids and endpoints denoted as: 
ETV1/ETV4. See Table 3.4 for homologous residues and numbering for ETV1 
and ETV4. (c) Portions of the ETV1, left, and ETV4, right, structures, in van der 
Waals sphere format to show hydrophobic interactions between the ETS domain 
and H4. (d) Fold Inhibition of ETV4 FL in its wild-type form, WT (n=35), or with 
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Figure 3.5 Connection between CID and DNA-recognition α-helix H3 mediates 
autoinhibition.  (a) Equilibrium dissociation constant, KD, values for uninhibited 
and CID-inhibited ETV1, amino acids 332-425 (n=6) and 332-430 (n=7), 
respectively, ETV4, 337-430 (n=25) and 337-436 (n=23), and ETV5, 364-457 
(n=4) and 364–463 (n=7). “*” Indicates p < 0.05. (b) Crystal structure of 
uninhibited ETV5, amino acids 364-457, showing the truncated H4 and the same 
selected sidechains as in Figure 3.4. (c) H3 positioning from CID-inhibited ETV4, 
gray; uninhibited ETV5, red; and ETV4 bound to DNA, pink (4UUV.pdb)27. 
Structures were aligned to DNA-bound ETV4 across the entire protein sequence 
(See Fig. 3.6). Met457 of ETV5, the homologous residue to Leu430 in ETV4, is 
not in frame due to the repositioning of H4 in the uninhibited ETV5 crystal 
structure. See Table 3.4 for homologous residues and numbering for ETV4 and 
ETV5. (d) Comparison of KD values for ETV4 FL in its wild-type form, WT (n=35), 
or with point mutations Leu430Ala (n=11), Ile407Ala (n=4), or both Ile407Ala and 
Leu430Ala (n=4). “*” Indicates p < 0.05. Fold difference for KD values are relative 































































































Figure 3.6 Crystal packing of uninhibited ETV5. (A) and (B) distinguish the two 
molecules of uninhibited ETV5, amino acids 364-457. The contacts between (A) 
and (B) may affect the position of truncated α-helix H4 (cyan) as compared to the 
position in solution or in the intact H4 in inhibited ETV5.  
  




Figure 3.7 Structural comparison of CID-inhibited ETV1 and ETV4 with 
uninhibited ETV5. (a) Root mean square deviations were calculated for backbone 
atoms to compare the crystal structures of uninhibited ETV5, amino acids 364-
457, with CID-inhibited ETV1, 331-435, and ETV4, 337-441, and DNA-bound 
ETV4, 337-441 (4UUV.pdb)27. Secondary structural elements are defined as in 
Figure 3.4 and the numbering refers only to ETV4. For subsections of the entire 
structure (e.g., H1, 343-358), the different structures were realigned based on 
that particular subsection and RMSD values correspond to backbone atoms 
within that subsection. The CID-inhibited ETV1 and ETV4 structures are very 
similar and have low RMSD values. The ETS domain overall (H1-S4) as well as 
most subsections (H1, S1-S2, H2, and S3-S4) have similar RMSD values for the 
remaining comparisons. In contrast, the RMSD value for H3 is relatively lower for 
the uninhibited ETV5 / DNA-bound ETV4 comparison than for the CID-inhibited 
ETV1/ETV4 versus uninhibited ETV5 or the CID-inhibited ETV4 versus DNA-
bound ETV4 comparisons. This indicates that H3 is more similar in the 
uninhibited and DNA-bound states than in the CID-inhibited state. (b) Sequence 
alignment of ETV1/4/5 helix H4 from H. sapiens (Hs), M. musculus (Mm), and D. 
rerio (Dr) colored according to Clustal Omega61. The red arrow and cyan cylinder 
indicate β-strand S4 of the ETS domain and H4, respectively. The two vertical 
dashed lines, black and gray, identify truncation endpoints that cause activation 
or retain CID inhibition, respectively. (c) CID-inhibited ETV4 in its apo (this study) 
and DNA-bound forms (4UUV.pdb)27 were aligned based on the entire protein 
sequence. ETS domain and inhibitory residues are colored gray and dark teal, 
respectively, for the apo ETV4 and pink and cyan, respectively, for the DNA-
bound ETV4. Selected side chains are displayed in stick format as in Figure 3.4. 
Comparison with the apo form demonstrates that there are subtle shifts of 
backbone atoms in the C-terminus of H3, as well as H4. 










Data collection and refinement statistics 
 
  
    CID-Inhibited ETV1  
332-435                       
CID-Inhibited ETV4  
337-441                       
Uninhibited ETV5  
364-457  
Data Collection       
Crystal BETV108 CETV402 AEAV501 
Processing software HKL2000 HKL2000 HKL2000 
Beamline SSRL 7-1 SSRL 7-1 SSRL 7-1 
Wavelength  1.0000 1.0000 1.1271 
Detector type Q315 CCD Q315 CCD Q315 CCD 
Collection date 2/7/13 2/7/13 1/12/13 
Space group P3121 P3121 C2221 
Unit cell (50.2, 50.2, 69.3) (50.9, 50.9, 68.6) (57.5, 65.7, 53) 
Resolution (Å) 55.00 - 1.40 45.00 - 1.10 30.00 - 1.80 
Resolution (Å) (high-resolution shell) 1.45 - 1.40 1.13 - 1.10 1.86 - 1.80 
# Reflections measured 705,596 1,577,832 50,220 
# Unique reflections 20,493 42,215 9,566 
Redundancy 34.4 37.4 5.2 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 99.2 (97.3) 
<I/σI> 16 (1.9) 5 (0.9) 9 (1.0) 
Mosaicity (°) 0.3 0.2 0.09 
R(pim) 0.018 (0.243) 0.020 (0.676) 0.039 (0.363) 
Refinement    
Refinement software PHENIX.REFINE PHENIX.REFINE PHENIX.REFINE 
Resolution (Å) 30.0 - 1.40 45.00 - 1.10 30.0 - 1.80 
Resolution (Å) (high-resolution shell) 1.47 - 1.40 1.13 - 1.10 2.05 - 1.80 
# Reflections used for refinement 20,457 42,112 8163 
# Reflections in Rfree set 967 1,988 410 
Rcryst (high-resolution shell) 0.157 (0.217) 0.181 (0.361) 0.186 (0.247) 
Rfree (high-resolution shell) 0.178 (0.237) 0.201 (0.388) 0.234 (0.285) 
RMSD: bonds (Å) / angles (°) 0.006 / 1.175 0.005 / 1.047 .008 / 1.456 
<B> (Å2): All protein atoms / # atoms 16.1 / 890 16.5 / 1013 29.7 / 851 
<B> (Å2):  water molecules / # water 32.8 / 114 28.9 / 125 37.1 / 81 
Ramachandran favored (%)   87.5 91.8 87.7 
Ramachandran additionally allowed (%) 12.5 8.2 12.3 
    Values in parentheses are for highest-resolution shell. One crystal was used to measure the data for each 
structure. 
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Figure 3.8 The CID perturbs the dynamic DNA-recognition α-helix H3. (a) 
Overlaid 15N-HSQC spectra of uninhibited ETV4, amino acids 328-430, red, and 
CID-inhibited ETV4, 313-446, purple. (b) Secondary structure propensities for the 
two ETV4 fragments calculated from 1HN, 15N, 13Cα, 13Cβ, 13CO chemical shifts62. 
Helix, strand (shown as negative values), and coil (not shown) propensities sum 
to 1. Colored histogram bars identify amides in helices or stands of the ETS 
domain, red, and CID, cyan, as observed in the X-ray crystal structure of ETV4, 
top cartoon. (c) KD values for the ETV4 fragments used for NMR spectroscopy 
studies, red (n=4) or purple (n=4), compared to those used for X-ray 
crystallography, black (n=25 and n=23 for ETV4 337-430 and ETV4 337-436, 
respectively). (d,e) Amide chemical shift perturbations (Δδ = [(ΔδH)2 + (0.2ΔδN)2 
]½) for corresponding residues in the spectra of (a) are mapped onto the crystal 
structure of ETV4 337-436 and plotted as a histogram. Perturbed residues with 
Δδ > 0.025 ppm, horizontal dashed line, are highlighted in red on the structure. 
(f,g) Amide HX protection factors of uninhibited ETV4 328-430, are mapped onto 
the crystal structure of ETV4 337-441, left, and plotted as a histogram, right. 
Green spheres indicate protection factors ≿ 1000, determined from 1H/2H 
exchange, and ≾50 obtained from 1H/1H CLEANEX measurements. The orange 
spheres and dashed histogram lines identify amides with resolved, assigned 15N-
HSQC signals that exchanged too fast or too slow to be quantitated by these two 
approaches, respectively, and thus have protection factors in the range of ~ 50 to 
1000. Missing values correspond to prolines or residues with unassigned or 
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Figure 3.9 The NID is intrinsically disordered.  (a) Left, the 15N-HSQC spectrum 
of the ETV4 NID, amino acids 165-336, red. Right, the overlapped spectra of 15N-
labled ETV4 NID alone, red, and ligated to the unlabeled ETS domain and CID, 
amino acids 337-436, blue. (b) Secondary structure propensities for a-helical and 
β-strand, top, and random coil conformations, bottom, calculated from mainchain 
chemical shifts (1HN, 15N, 13Cα, 13Cβ, 13CO) of the NID with the algorithm MICS 62. 
(c) Comparison of 15N-HSQC amide chemical shifts (Δδ = [(ΔδH)2 + (0.2ΔδN)2 ]½), 
top, and peak intensities, bottom, for the NID from the two spectra in (a). The 
15N-HSQC spectrum of the intein-ligated species was assigned by comparison 
with that of the isolated NID, and red bars indicate amide signals that could not 
be confidently identified. Missing histogram bars correspond to unassigned 
amides in the isolated NID and prolines. 
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Figure 3.10 Circular dichroism of the NID. Circular dichroism spectrum of the 
ETV4 NID, amino acids 165-336, at 4 °C and pH 7.9, is indicative of a random 
coil conformation. Three scans were collected in series and averaged after 
visually verifying their consistency. 
  









Figure 3.11 The NID perturbs the DNA-recognition α-helix H3 and the CID.  (a) 
Overlaid 15N-HSQC spectra of ETV4 ETS domain and CID alone, amino acids 
337-436, red, and with the unlabeled NID, amino acids 165-336, added via intein 
ligation, blue. Selected peaks are labeled with corresponding residues. (b, c) The 
amide chemical shift perturbations, (Dd = [(DdH)2 + (0.2DdN)2 ]½), resulting from 
the ligated NID are displayed in histogram format and mapped onto the structure 
of ETV4 ETS domain and CID. Blue, Dd > 0.025 ppm; gray, Dd < 0.025 ppm, 
prolines, and residues with unassigned NMR signals 
 
  















Figure 3.12 Acetylation relieves NID-dependent autoinhibition. (a) Binding 
isotherms for ETV4 (FL), unacetylated, black, and acetylated at Lys226, green, 
or Lys260, orange. Data points and error bars correspond to the mean and 
standard error of the mean from four replicates. (b) Quantification of fold 
inhibition comparing ETV4 FL with no acetylation with ETV4 K226Ac and 
K260Ac. The DNA binding of ETV4 Lys226Ac (KD, 30 ± 6 x 10-11 M) and ETV4 
Lys260Ac (KD, 51 ± 3 x 10-11 M) was inhibited 4 ± 1 fold and 7 ± 1 fold, 
respectively, whereas, ETV4 (KD, 83 ± 8 x 10-11 M) with no acetylation was 
inhibited 14 ± 2 fold. All fold inhibition values are relative to uninhibited ETV4 
337-430 (KD, 6.1 ± 0.6 x 10-11 M). “***” Indicates p < 0.001. 
  










Figure 3.13 Autoinhibition in ETS family of transcription factors (ETS domain, 
red; inhibitory elements, cyan). (a) Model for autoinhibition in ETV1/4/5 subfamily 
illustrating a hypothetical equilibrium between apo forms that are inactive (left) 
and active (center) for binding DNA, as well as the DNA-bound form (right). 
Parameters that influence this equilibrium are listed. Dotted cyan line refers to 
the disordered NID. (b) Examples of structurally-characterized autoinhibited ETS 
factors: ETV1/4/5 subfamily (this study), ETS19,14,15, ERG11, and ETV610,12,13. 
Dotted cyan line for ETS1 refers to the disordered serine-rich region (SRR). 
 
  




Table 3.4  
 Numbering of homologous amino acids for ETV1, ETV4, and ETV5 
 
ETV1 ETV4 ETV5 
Lys228 Lys226 Lys263 
Lys257 Lys260 Lys293 
Gly333 Gly339 Gly366 
Trp338 Trp344 Trp371 
Leu344 Leu350 Leu377 
Arg394 Arg400 Arg427 
Tyr395 Tyr401 Tyr428 
Tyr396 Tyr402 Tyr429 
Tyr397 Tyr403 Tyr430 
Lys399 Lys405 Lys432 
Ile401 Ile407 Ile434 
Lys404 Lys410 Lys437 
Phe414 Phe420 Phe447 
Asp417 Glu423 Asp450 
Ala420 Ala426 Ala453 
Phe422 Phe428 Phe447 
Ser423 Ser429 Ser456 
Met424 Leu430 Met457 
Phe426 Phe432 Phe459 
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Abstract 
The activation domains of DNA sequence-specific transcription factors 
recruit the Mediator complex through interactions with individual subunits. 
Previously, it was demonstrated that the N-terminal activation domain of ETV5 
interacts with Mediator subunit 25 (MED25). We establish in this report that both 
the N-terminal activation domain and the DNA-binding domain of ETV4 interact 
with MED25. The interactions of each of these ETV4 domains with MED25 
display distinct kinetics and combined, they contribute to a higher-affinity 
interaction of full-length ETV4 with MED25. Interaction with MED25 is selective 
for the ETV1/4/5 subfamily of ETS transcription factors as ETS1 and EHF do not 
appreciably bind to MED25. This selectivity arises from divergent amino acids 
within the ETS domain and distinct flanking sequences outside of, but proximal 
to, the ETS domain. Our findings are the first example of an ETS DNA-binding 
domain interacting with a Mediator subunit and demonstrate that both activation 




Sequence-specific DNA-binding transcription factors regulate eukaryotic 
transcription through interactions with general transcription factors, coactivators, 
and chromatin remodelers in order to recruit and affect the activity of RNA 
polymerase II (Pol II)1. The Mediator complex is a critical transcriptional 
coactivator that serves as a primary conduit for transmitting regulatory signals 
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from specific transcription factors to Pol II2. The 26 subunits of mammalian 
Mediator (not including the CDK8 kinase module) form distinct modules termed 
the head, middle, and tail modules. A reconstituted complex comprised of 15 
subunits from the head and middle modules represents the minimal functional, or 
“core”1, complex required for the general coactivator function of Mediator3. In 
contrast, the presence of and requirement for other subunits of Mediator, 
primarily those that compose the tail module, is more variable and gene-specific4-
11. As individual transcription factors recruit the Mediator complex through distinct 
Mediator subunits5,7,12,13, the simplest model to explain gene-specificity is that 
non-core Mediator subunits are only required for the transcription of the genes 
that they are directly recruited to via interactions with sequence-specific 
transcription factors2. This model accurately depicts many Mediator subunit-
regulated genes4-6,9-11, although more complex mechanisms involving 
transcription factor partnerships or recruitment of transcriptional repressors have 
been described8,14-16. 
Transcription factors primarily utilize activation domains (ADs) to recruit 
Mediator subunits. ADs are often short peptide sequences that are disordered in 
isolation, but form amphipathic α-helices when binding to their Mediator subunit 
targets17-21. Less frequently DNA-binding domains (DBD) of transcription factors 
have been implicated in interactions with Mediator subunits22,23. 
ETV1, ETV4, and ETV5 form a subgroup of the ETS (E26-transformation 
specific) family of transcription factors. This subgroup is aberrantly 
overexpressed in a subset of prostate cancers24-26, which promotes PI3-kinase 
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and RAS signaling pathways resulting in an aggressive and metastatic disease 
phenotype27,28. Previously it was demonstrated that ETV5 interacts with the 
activator interacting domain (ACID) of Mediator subunit 25 (MED25) through its 
N-terminal AD20,29. Due to chromosomal rearrangements, prostate cancers 
frequently harbor truncations of ETV1 that lack the AD, suggesting that the AD is 
dispensable for ETV1’s function in prostate cancer30,31. Previously characterized 
interactions between VP16 and MED25 demonstrated that the two ADs of VP16 
bind to separate faces of the MED25 ACID domain17,18. The N-terminal ADs of 
ETV5 and VP16 interact with same surface on MED25, therefore we 
hypothesized that ETV1/4/5 subfamily factors contain an additional MED25-
binding site outside of the AD that can interact with MED25 in the absence of the 
AD. 
Here we demonstrate that both the N-terminal AD and the DBD of ETV4 
interact with the ACID domain of MED25. The kinetics of each of these 
interactions are distinct and combined these interactions contribute to a higher-
affinity binding of full-length ETV4 with MED25.  Using NMR spectroscopy, we 
detected partially overlapping, yet distinct, faces of the ACID domain interact with 
these two regions of ETV4. Reciprocal NMR experiments determined that the 
ACID domain of MED25 perturbs a broad surface on the DNA-binding domain of 
ETV4. Mutagenesis of residues in the AD or in the DBD of ETV4 both weaken 
the affinity of the interaction with MED25, confirming the contribution of both 
domains in this interaction. This is the first reported interaction between a DBD in 
an ETS factor and a Mediator subunit and provides a rationale for selective 
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The activation and ETS domains of ETV4 bind to MED25 
We used biolayer interferometry to measure the interaction between 
MED25 ACID (amino acids 391-553) and truncations of ETV4 (Fig. 4.1). The N-
terminal AD, amino acids 43-84, bound to MED25 with a KD of 680 ± 60 nM (Fig. 
4.1a and Table 4.1). This value is comparable to previous measurements of the 
interaction between the AD of ETV5 and MED25 by fluorescence polarization 
(KD, 580 ± 20 nM) and by isothermal calorimetry (KD, 540 ± 40 nM) 20,29. 
Intriguingly, full-length ETV4 (amino acids 1-484) bound to MED25 with an 
approximately 100-fold higher affinity (KD, 6 ± 1 nM). Correspondingly, ETV4 
165-484, which lacks the AD, also bound to MED25 with a slightly higher affinity 
than that of the AD (KD, 300 ± 80 nM). Interestingly, the kinetics of the N-terminal 
and C-terminal portions of ETV4 interacting with MED25 differed (Fig. 4.1b and 
Fig. 4.2). Whereas the AD had association and dissociation rate constants (ka 
and kd, respectively) that reflected relatively fast kinetics of interaction, ETV4 
165-484 had ka and kd values, indicating that the interaction with this fragment 
and Mediator is defined by relatively slow kinetics. The interaction between full-
length ETV4 and MED25 had a comparable ka to the AD – MED25 interaction 
and comparable kd to the ETV4 165-484 – MED25 interaction. Therefore, we 
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concluded that both the N-terminal AD and a C-terminal component of ETV4 
contribute to the higher-affinity binding of full-length ETV4 with MED25. 
To pinpoint the region(s) within ETV4 165-484 that are responsible for 
interaction, with MED25 we tested further truncations. ETV4 165-436 interacts 
with MED25 with a KD that is indistinguishable from ETV4 165-484 (Fig. 4.1a), 
although the kinetics of these interactions are slightly different (Fig. 4.1b). ETV4 
165-336 only measurably interacted with MED25 at concentrations greater than 
50 mM, which precluded a full titration to determine the exact KD of this 
interaction. An estimate based on only the highest concentration suggests that 
ETV4 165-336 interacts with MED25 with an approximate KD of ~ 5 mM (Fig. 
4.2f). Unfortunately, ETV4 337-436 nonspecifically bound to the streptavidin 
sensors in the absence of MED25 (Fig. 4.2g), which precluded measuring the 
interaction strength between this truncation and MED25. Despite our inability to 
measure this interaction, we interpreted the weak interaction of ETV4 165-336 - 
MED25 (~ 5,000,000 nM), in comparison with the ETV4 165-436 - MED25 
interaction (290 ± 70 nM), to indicate that the C-terminal contribution in binding 
with MED25 requires the DBD of ETV4, amino acids 337-436. 
Next we tested the specificity of the interaction with MED25 amongst ETS 
transcription factors. The N-terminal activation domain is conserved between 
ETV1, ETV4, and ETV5, but is not detected by sequence similarity in other ETS 
proteins. However, there is conservation amongst other ETS factors for the 
highly conserved C-terminal component, which spans the ETS domain. Unlike 
ETV4, ETS1 and EHF, two ETS factors outside the ETV1/4/5 subfamily, do not 
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measurably interact with MED25 (Fig. 4.3). This suggests that the specific C-
terminal component(s) of ETV4 responsible for interaction with MED25 are not 
widely conserved across ETS proteins. 
 
ETV4 ETS domain and AD perturb distinct surfaces  
of MED25 
To obtain amino acid-resolution of the interactions between ETV4 and 
MED25, we utilized NMR spectroscopy and a previously characterized 15N-
HSQC spectrum of the ACID domain of MED2517,18. We titrated 15N-labeled 
MED25 ACID with either the AD, amino acids 43-84, or the DBD, amino acids 
337-436, of ETV4. The addition of the AD of ETV4 resulted in widespread 
changes in the 15N-HSQC spectrum of MED25 ACID (Fig. 4.4a) in the form of 
chemical shift perturbations (Fig. 4.4b) and changes in the relative intensities of 
peaks (Fig. 4.4c). In comparison, the addition of the DBD resulted in subtler 
changes in the spectrum of MED25 ACID (Fig. 4.5). We mapped the strongest 
perturbations from both ETV4 titrations (Fig. 4.4b,c and Fig. 4.5b,c) onto the 
structure of MED25 ACID (Fig. 4.6). The ACID domain is a seven-stranded β-
barrel with four α-helices (Fig. 4.6a). Two of the α-helices, H2 and H4, are 
oriented parallel to the lengthwise edge of the β-barrel. The ETV4 AD and ETS 
domain perturb distinct, yet partially overlapping, subsets of surface-exposed 
residues on MED25 ACID. The overlapping perturbations are centered on H2 
and H4 (Fig. 4.6b,c). The distinct portions of the AD- and DBD-perturbed 
surfaces reside on opposing sides of the β-barrel, with the AD-perturbed residues 
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on the S3/S5 side and the DBD-perturbed residues on the S4/S6/S7 side. 
Therefore, we conclude that the DBD and the AD of ETV4 interact with distinct, 
yet overlapping surfaces on MED25 ACID. 
 
MED25 ACID activates the DNA-binding of ETV4  
through interaction with divergent residues 
Previously, studies structurally-characterized the interaction between the 
ETV5 AD and MED25, demonstrating that the AD becomes more helical in 
character in the MED25-bound state and that the hydrophobic residues in the 
amphipathic α-helix of the AD are critical for this interaction20. Based on the 
robust sequence conservation between the AD of ETV1, ETV4, and ETV5 (Fig. 
4.7), we surmised that the ETV4 AD would interact with MED25 in a conserved 
fashion. Therefore, we focused on characterizing the residues that are important 
for the DBD interaction with MED25. 
We titrated 15N-labeled ETV4 DBD, amino acids 337-436, with unlabeled 
MED25 ACID (Fig. 4.8a). MED25 perturbed a broad surface on the ETV4 DBD 
with residues from all four α-helices and the β-sheet being influenced (Fig. 
4.8c,d). Because of the observed selectivity for MED25 interacting with ETV4 but 
not ETS1 or EHF, we examined the conservation of the residues perturbed by 
MED25. In general for ETS transcription factors, the interior core of the ETS 
domain and amino acids that form the DNA-binding interface were most highly 
conserved (Fig. 4.9). In contrast, exterior facing amino acids that do not form the 
DNA-binding interface were more divergent. The amino acids that were 
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perturbed by MED25 also reflected this trend (Fig. 4.9b). In addition, the peaks 
with the largest chemical shift perturbation and change in relative peak 
intensities, Ser429 and Glu425, respectively, reside just outside of the ETS 
domain in helix H4, a structural element that is unique to the ETV1/4/5 subfamily. 
Therefore, we reasoned that surface-exposed, divergent amino acids in the ETS 
domain and H4 are critical for the interaction between ETV4 and MED25. 
To test the functional importance of individual amino acids, we mutated 
select residues to alanine in the context of full-length ETV4 and used biolayer 
interferometry to analyze the affect of these mutations on the binding affinity of 
MED25 ACID for ETV4. Mutations from the AD, F54A, and the DBD, S429A, 
resulted in 10- and 30-fold increases, respectively, in KD values (Fig. 4.10a and 
Table 4.2). Interestingly, the AD mutation F54A had more of an influence on the 
ka of the interaction whereas the DBD mutation S429A had more of an influence 
on the kd of the interaction (Fig. 4.10b and Table 4.2). These mutants support 
the observation from ETV4 truncations (Fig. 4.1) that the AD and the DBD rate 
constants reflect relatively fast and slow kinetics, respectively, for these domains’ 
interactions with MED25. 
We previously demonstrated that helix H4 inhibits the DNA-binding of the 
ETS domain of ETV4 (Chapter 3). Therefore, we next tested whether interaction 
with MED25 modulates the DNA-binding affinity of ETV4. Addition of MED25 
results in a more prominent ETV4:DNA EMSA band (Fig. 5.11a). As a control, 
equivalent amounts of MED25 had no effect on DNA in the absence of ETV4. 
MED25 also slightly increases the affinity of ETV4, but not ETS1, for DNA (Fig. 
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5.11b). While this activation is slight (1.4 ± 0.2 fold), it is approaching statistical 
significance (p = 0.1 in a heteroscedastic t-test) and similar in magnitude to the 
level of autoinhibition conferred by H4 (1.9 ± 0.3 fold) (Chapter 3). Therefore, this 
data suggests that interaction with MED25 activates the DNA-binding of ETV4 
through relief of H4-mediated autoinhibiton of the ETS domain. 
 
Discussion 
ETV4 AD and DBD contribute to MED25 interaction 
Here, we have observed a bipartite interaction between full-length ETV4 
and the ACID domain of MED25. Both the AD and the DBD of ETV4 are capable 
of independent interaction with MED25 ACID. The higher-affinity interaction of 
full-length ETV4 and MED25 reflects the fast association rate of the AD-MED25 
interaction and the slow dissociation rate of the DBD-MED25 interaction. In 
support of distinct contributions from the AD and DBD, these domains interact 
with distinct, yet overlapping regions on the surface of MED25 ACID. Interaction 
with MED25 is not conserved in the ETS transcription factors ETS1 and EHF. 
While the AD of ETV1/4/5 is specific to that subfamily, the presence of a 
conserved ETS domain in all ETS transcription factors would seemingly 
confound the specificity of interaction amongst ETS factors with MED25. 
However, we found that MED25 perturbs the b-sheet of the ETS domain, and α-
helix H4 that resides just C-terminal of the ETS domain. The β-sheet is poorly 
conserved amongst ETS factors, and H4 is specific to the ETV1/4/5 subfamily in 
terms of its sequence and relative positioning relative to the ETS domain. 
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Therefore, we suggest that these two components create a unique interface for 
MED25 that is distinct from most, if not all, ETS factors outside of the ETV1/4/5 
subfamily. The point mutation of serine 429 to alanine drastically diminishes the 
interaction of ETV4 with MED25, reinforcing the importance of H4 to this 
interaction. Lastly, we find that the interaction of MED25 strengthens the binding 
of ETV4 to DNA, likely through ablation of the autoinhibition that H4 imparts on 
the ETS domain. In summary, we have found that the interaction with MED25 
involves both the AD and DBD and activates the DNA binding of ETV4. 
The ETV4 AD-MED25 interaction is consistent with the previously 
reported characterizations of the ETV5 AD-MED25 interaction20,29 based on the 
functional importance of conserved hydrophobic residues in both ADs, and the 
similar interaction surface with MED25 for both ADs. In contrast, we found that 
the DBD of ETV4 also interacts with MED25. All ETV4 amino acids implicated by 
NMR in the DBD-MED25 interaction are conserved in ETV1 and ETV5. In 
addition, ETV1, ETV4, and ETV5 have structurally-conserved DBDs32. Therefore, 
it is highly likely that the DBD-MED25 interaction observed here for ETV4 is also 
conserved in ETV1 and ETV5. 
 
Mediator interactions with other ETS transcription  
factors 
The TCF subfamily of ETS factors, ELK17,9,33, ELK39, and ELK49, as well 
as ELF319 interact with Mediator subunit 23 (MED23). The transcriptional activity 
of ELK1 was largely ablated in the absence of MED23, whereas ELK3 and ELK4 
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demonstrated a more modest dependence on MED239. This finding suggested 
that ELK3 and ELK4 are capable of interacting with the Mediator complex even in 
the absence of MED23. However, recent work suggests that ELK1 can also 
associate with the Mediator complex even in the absence of MED2333. The 
redundancy of ELK1, ELK3, and ELK4 interacting with multiple subunits of the 
Mediator complex is a common feature that has been noted for the ADs of other 
transcription factors34-37.  
The ADs of ETV1/4/5 and TCF subfamilies differ in sequence (Fig. 4.7). 
However, due to the flexible nature of ADs, functional binding to common protein 
targets is observed even in the case of significant sequence divergence21. For 
example, the ADs of ATF6 and VP16, which also bind to MED25 ACID17,18,38, 
show no sequence conservation with ETV1/4/5 ADs. Further investigation is 
warranted to investigate whether ETV1/4/5 and TCF ADs have overlapping 
Mediator subunit targets. Additionally, the above studies on TCF factors utilized 
only the AD of these proteins. Further analysis of TCF, or other ETS factors, with 
Mediator subunits should also examine the possible contribution of the DBDs to 
these interactions. 
 
ETV4-MED25 interaction and prostate cancer 
ETV1/4/5 subfamily factors are often overexpressed in prostate cancer, 
and in a subset of these instances, the N-terminus of ETV1, including the AD, is 
truncated due to chromosomal rearrangements30,31. This truncation has been 
shown to increase the stability of ETV1, as two of the main E3 ubiquitin ligase 
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recognition sites are located in the N-terminus and are lost due to the 
truncation39,40. Here we have demonstrated that even with the loss of the AD, 
ETV1/4/5 subfamily factors can still interact with MED25 through their DBD. The 
requirement of interaction with MED25 for ETV1/4/5 subfamily factors’ role in 
prostate cancer remains to be established. Disruption of ELF3-MED23 interaction 
with a small molecule inhibitor effectively decreased the expression of the 
receptor tyrosine kinase ERBB2 and selectively killed breast cancer cell lines19,41. 
Therefore, perturbation of transcription factor–mediator interfaces are tractable 
potential therapeutic targets42. Future studies will establish whether the ETV1/4/5 
– MED25 interface could be a molecular target with therapeutic potential. 
 
Methods 
Protein expression and purification 
Full-length ETS factors and and truncated ETV4 fragments were cloned 
into the pET28 (Novagen) bacterial expression vector using sequence- and 
ligation-independent cloning (SLIC)43. MED25 ACID (amino acids 391-553) was 
cloned into a vector with N-terminal GST, avitag, and HIS6 tags for biolayer 
interferometry and pET28 for NMR spectroscopy. 
All proteins were expressed in (λDE3) Escherichia coli cells. MED25 ACID 
and ETV4 1-164, 43-84, and 337-436 expressed into the soluble fraction, and 
were grown in 1L cultures of Luria broth (LB) at 37 °C to OD600 ~ 0.7 – 0.9, 
induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG), and grown at 30 
°C for ~ 3 hours. For MED25 ACID protein used in BLI, 1mL of 50mM biotin was 
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added at the induction point. Cells were centrifuged at 6,000 RPM in a JLA 8.1 
rotor (Beckmann), resuspended in a buffer containing 25 mM Tris, pH 7.9, 
200mM NaCl, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM 2-
mercaptoethanol (BME), and 1 mM phenylmethanesulfonylfluoride (PMSF), and 
snap-frozen in liquid nitrogen. After 3-5 freeze-thaw cycles, cells were lysed by 
sonication and ultracentrifuged at 40k RPM in a Beckman Ti45 rotor. The soluble 
fraction was then loaded onto a Ni2+ affinity column (GE) and eluted over 20 
column volumes of a 5-500mM imidazole gradient. For MED25 ACID used in BLI, 
protein eluted from the Ni2+ column was loaded onto a GST affinity column and 
eluted with the same buffer with 15mM glutathione. Elutions were then dialyzed 
overnight into 25 mM Tris pH 7.9, 10% glycerol (v:v), 1 mM EDTA, 50 mM KCl 
and 1 mM dithiothreitol (DTT). After ultracentrifugation as previously described, 
proteins were purified over a SP-sepharose cation exchange column (GE) (ETV4 
337-436 and MED25 391-553) or Q-sepharose anion exchange column (GE) 
(ETV4 1-164 and 43-84) using a 50 – 1000 mM linear gradient of KCl. Proteins 
were then further purified over a Superdex 75 gel filtration column (GE 
biosciences) in 25 mM Tris pH 7.9, 10% glycerol (V:V), 1 mM EDTA, 300 mM 
KCl, and 1 mM DTT. Purified proteins were concentrated on a 10-kDa molecular 
weight cutoff (MWCO) centricon device, snap-frozen in liquid nitrogen, and 
stored in single-use aliquots at -80° C for subsequent NMR or biolayer 
interferometry studies. 
Full-length ETV4 and ETV4 165-436, 165-336, and 165-484 expressed 
into the insoluble fraction using an autoinduction protocol44. Briefly, bacteria in 
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250 mL of autoinduction media were grown in 4 L flasks at 37 °C to an OD600 ~ 
0.6 – 1. The temperature was then reduced to 30 °C and cultures were grown for 
another ~ 12 – 24 hours. Final OD600 values were typically ~ 6 – 12, indicating 
robust autoinduction. Harvested cells were resuspended as described above, 
sonicated and centrifuged at 15k rpm in a JA-17 rotor (Beckman) for 15 minutes 
at 4 °C. The soluble fraction was discarded and this procedure was repeated with 
the pellet / insoluble fraction twice more to rinse the inclusion bodies. The final 
insoluble fraction was resuspended with 25 mM Tris pH 7.9, 1 M NaCl, 0.1 mM 
EDTA, 5 mM imidazole, 2 mM BME, 1 mM PMSF, and 6 M urea. After sonication 
and incubation for ~ 1 hour at 4 °C, the sample was centrifuged for 40k rpm for at 
least 30 minutes at 4 °C. The soluble fraction was loaded onto a Ni2+ affinity 
column (GE Biosciences) and refolded by immediately switching to a buffer with 
the same components as above, except lacking urea. After elution with 5 – 500 
mM imidazole, the remaining purification steps using ion-exchange and size-
exclusion chromatography were performed as described above. A Q-sepharose 




Data were collected using an Octet Red96 instrument (ForteBio) and 
processed with the intrument’s software. 500 nM of biotinylated MED25 protein 
was immobilized using high-precision streptavidin sensors (ForteBio) for ~ 100 
seconds to get a response of ~ 1.5 nm. Interaction experiments were conducted 
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using 150 mM NaCl, 25 mM Tris pH 7.9, 1 mM Tris(2-carboxyethl)phosphine 
(TCEP)(Sigma), 5 ug/mL bovine serum albumin (Sigma) and 0.5% (v:v) Tween20 
(Sigma). Biosensors were dipped in various concentrations of the analyte of 
interest to measure association, and transferred back to buffer wells for 
monitoring dissociation. For quantitative analysis, six titration points of ETV4, 
with exact concentrations varying dependent on the affinity of the interaction 
between that ETV4 truncation/mutant and MED25, were fit using a global (full) 
analysis. Kinetic constants were determined from the mathematical fit of a 1:1 
binding model. Mean and standard deviation of KD, ka, and kd values from at least 
three independent experimental replicates are displayed in figures and tables. 
 
NMR spectroscopy 
1H-15N HSQC measurements were recorded on a 500MHz Varian Inova 
spectrometer at 25°C in NMR buffer (20mM Sodium Phosphate, pH 6.5, 200mM 
NaCl, 2mM Dithiothreitol (DTT), 1mM EDTA acid, 10% D2O). Assignments for 
MED25 ACID17,45 and ETV4 337-436 (Chapter 3) were transferred from previous 
work and titration data processed and analyzed using Sparky46 (UCSF). 
 
Electrophoretic mobility shift assays (EMSAs) 
DNA-binding assays of ETS factors utilized a duplexed 27-bp 
oligonucleotide with a consensus ETS binding site: 5’-
TCGACGGCCAAGCCGGAAGTGAGTGCC-3’ (arbitrarily assigned as “top” 
strand) and 5’-TCGAGGCACTCACTTCCGGCTTGGCCG-3’ ("bottom" strand). 
	   113	  
Boldface GGAA indicates the consensus ETS binding site motif. Each of these 
oligonucleotides, at 2 µM as measured by absorbance at 260 nM on a NanoDrop 
1000 (Thermo Scientific), were labeled with [g-32P] ATP using T4 polynucleotide 
kinase at 37 °C for ~ 30 – 60 minutes. After purification over a Bio-Spin 6 
chromatography column (Bio-Rad), the oligonucleotides were incubated at 100 
°C for ~ 5 minutes, and then cooled to room temperature over 1 – 2 hours. The 
DNA for EMSAs was diluted to 1 x 10-12 M and held constant, whereas ETV4 and 
ETS1 concentrations ranged from 1 x 10-7 to ~1 x 10-12M. Protein concentrations 
were determined after thawing each aliquot of protein, using the Protein Assay 
Dye Reagent. Equivalent starting amounts (0.2 mg) of each protein utilized on a 
given day were run on an SDS-PAGE gel to confirm their relative concentrations. 
The binding reactions were incubated for 45 minutes at room temperature in a 
buffer containing 25 mM Tris pH 7.9, 0.1 mM EDTA, 60 mM KCl, 6 mM MgCl2, 
200 mg/mL BSA, 10 mM DTT, 100 ng/mL poly(dIdC), and 10% (v:v) glycerol, and 
then resolved on an 3.5 or 5% (w:v) native polyacrylamide gel at room 
temperature. The 32P-labeled DNA was quantified on dried gels by 
phosphorimaging on a Typhoon Trio Variable Mode Imager (Amersham 
Biosciences). Equilibrium dissociation constants (KD) were determined by 
nonlinear least squares fitting of the total protein concentration [P]t versus the 
fraction of DNA bound ([PD]/[D]t) to the equation [PD]/[D]t = 1/[1 + KD/[P]t)] using 
Kaleidagraph (v. 3.51; Synergy Software). Due to the low concentration of total 
DNA, [D]t, in all reactions, the total protein concentration is a valid approximation 
of the free, unbound protein concentration. Reported KD values represent the 
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Figure 4.1 N- and C-terminal regions of ETV4 interact with MED25. (a) 
Equilibrium dissociation constants (KD) of ETV4 truncations with MED25 as 
measured by biolayer interferometry. Values from three individual experiments 
are displayed as well as the mean and standard deviation. Two-tailed, 
heteroscedastic t-tests were used to calculate p-values between different 
fragments. The activation domain and ETS domain are abbreviated as AD and 
ED, respectively. (b) Comparison of association (ka) and dissociation (kd) rate 
constants for the interactions between different ETV4 truncations and MED25. 




Table 4.1 Interaction of ETV4 truncations with MED25 
 
     ETV4 KD (x 10-9 M)a ka (x 103 M-1s-1)a kd (x 10-3 s-1)a 
 43-84 680 ± 60 400 ± 100 290 ± 30 
 1-164 670 ± 60 330 ± 20 210 ± 20 
 165-436 290 ± 70 10 ± 4 2.7 ± 0.4 
 165-484 300 ± 80 0.80 ± 0.08 0.2 ± 0.1 
 1-484 6 ± 2 300 ± 100 1.7 ± 0.2 
 
     aMean and standard deviation from at least three individual 
experiments. 
 
    










Figure 4.2 Representative example of each interaction between ETV4 
truncations and MED25. Biolayer interferometry graphs for the interactions 
between MED25 and ETV4 1-484 (full length) (a), 165-484 (b), 165-436 (c), 43-
84 (N-terminal transactivation domain) (d), 1-164 (e), 165-336 (f), and 337-436 
(g). The left side of each graph is the association between MED25 and ETV4, 
and the right side is the dissociation. Concentrations of ETV4 truncations are 
displayed on the right side of each graph. The interaction affinity could not be 
measured for ETV4 337-436 (g) as there was too much nonspecific interaction 
between this truncation and the streptavidin biolayer tip. 
  


















Figure 4.3 MED25 does not interact with ETS1 or EHF. Biolayer interferometry 
graph showing the interaction between a single concentration (4 mM) of ETV4, 
EHF, or ETS1 with MED25. The lack of association between EHF or ETS1 with 
MED25 at this concentration suggests that these ETS factors either do not 













Figure 4.4 ETV4 43-84 perturbation of MED25 391-553. (a) Overlaid NMR 
spectra of 15N-MED25 391-553 alone (black) and with 1.2 molar equivalents of 
unlabeled ETV4 43-84 (blue). (b,c) Dd (ppm) and relative intensity of NMR peaks 
comparing spectra of MED25 391-553 alone and with ETV4 43-84. Schematic of 
secondary structure of MED25; arrows and rectangles represent β-strands and 
α-helices, respectively. 
  





Figure 4.5 ETV4 337-436 perturbation of MED25 391-553. (a) Overlaid NMR 
spectra of 15N-MED25 391-553 alone (black) and with 1.2 molar equivalents of 
unlabeled ETV4 337-436 (red). (b,c) Dd (ppm) and relative intensity of NMR 
peaks comparing spectra of MED25 391-553 alone and with ETV4 43-84. 
Schematic of secondary structure of MED25; arrows and rectangles represent β-
strands and α-helices, respectively. 
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Figure 4.6 ETV4 43-84 and 337-436 perturb distinct, but partially overlapping 
interfaces on MED25 391-553. (a) Cartoon depiction of MED25 ACID with two 
different views. (b) Spectral changes upon addition of ETV4 43-84, Dd > 0.125 
ppm or relative peak intensity < 0.05 (Fig 2b,c), are mapped onto the structure of 
MED25 391-553 (blue). MED25 391-553 oriented as in (a), but shown in surface 
format.  (c) Spectral changes upon addition of ETV4 337-436, Dd > 0.02 ppm or 
relative peak intensity < 0.35 (Fig 3b,c), are mapped onto the structure of MED25 
391-553 (red). MED25 ACID oriented as in (a), but shown in surface format. 
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Figure 4.7 Sequence alignments for activation domains of select ETS factors. (a) 
Alignment of the N-terminal AD from ETV1, ETV4, and ETV5. (b) Alignment of 
the AD from ELK1, ELK3, and ELK4. (c) Alignment as in (b), but with the AD 
from ELF3 also aligned. ELK1, ELK3, ELK4, and ELF3 are all capable of 






























Figure 4.8 MED25 interacts with a divergent interface on the DBD of ETV4. (a) 
Overlaid spectra of 15N-ETV4 ED, amino acids 337-436, alone (black), and with 
1.2 molar equivalents of unlabeled MED25 ACID (red). (b,c) Dd (ppm) and 
relative intensity of NMR peaks comparing spectra of ETV4 337-436 alone and 
with MED25 391-553. Schematic above histograms refers to the secondary 
structure of ETV4 DBD. Rectangles and arrows are α-helices and β-strands, red 
is ETS domain, cyan is divergent element specific to ETV1/4/5 subfamily. (d) 
Spectral changes upon addition of MED25 391-553; Dd > 0.02 ppm or relative 
peak intensity < 0.4, are mapped onto the structure of ETV4 337-436 in cartoon 
format. Perturbed residues are indicated by red coloring and side-chains are 
displayed in stick format. (e) Structure of ETV4 337-436 as in (d), but coloring 
refers to conservation of amino acids in the ETS domain. H4 is colored gray 
because is not structurally conserved in ETS proteins outside of the ETV1/4/5 
subfamily. See Figure 4.9 for further details on sequence conservation. 
  















Figure 4.9 Conservation of ETS domain. (a) Sequence alignment of ETS domain 
using Praline multiple sequence alignment tool47. Schematic above sequence 
alignment represents secondary structure elements of the ETS domain; 
rectangles and arrows represent α-helices and β-strands, respectively. (b) ETS 
domain from crystal structure of ETV4 shown in three different views and colored 
according to (a). Note that the highest conservation occurs in α-helices as well as 
core-facing amino acids and amino acids that are critical for DNA-binding (H3). In 
contrast, loops and the β-sheet are relatively less conserved. 
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ELF3 GTHLWEFIRD ILIHPELNEG LMKWENRH-- EGVFKFLRSE AVAQLWGQKK
ELF5 SSHLWEFVRD LLLSPEENCG ILEWEDRE-- QGIFRVVKSE ALAKMWGQRK
ELF2 TTYLWEFLLD LLQDKNTCPR YIKWTQRE-- KGIFKLVDSK AVSKLWGKHK
ELF1 TIYLWEFLLA LLQDKATCPK YIKWTQRE-- KGIFKLVDSK AVSRLWGKHK
ELF4 TIYLWEFLLA LLQDRNTCPK YIKWTQRE-- KGIFKLVDSK AVSKLWGKQK
SPDEF PIHLWQFLKE LLLKPHSYGR FIRWLNKE-- KGIFKIEDSA QVARLWGIRK
SPI1 KIRLYQFLLD LLRSGD-MKD SIWWVDKDKG TFQFSSKHKE ALAHRWGIQK
ETS1 PIQLWQFLLE LLTDKS-CQS FISWTG-D-- GWEFKLSDPD EVARRWGKRK
ETS2 PIQLWQFLLE LLSDKS-CQS FISWTG-D-- GWEFKLADPD EVARRWGKRK
ETV5 SLQLWQFLVT LLDDPA-NAH FIAWTG-R-- GMEFKLIEPE EVARRWGIQK
ETV4 ALQLWQFLVA LLDDPT-NAH FIAWTG-R-- GMEFKLIEPE EVARLWGIQK
ETV1 SLQLWQFLVA LLDDPS-NSH FIAWTG-R-- GMEFKLIEPE EVARRWGIQK
ELK4 AITLWQFLLQ LLQKPQ-NKH MICWTS-N-- DGQFKLLQAE EVARLWGIRK
GABPa QIQLWQFLLE LLTDKD-ARD CISWVG-D-- EGEFKLNQPE LVAQKWGQRK
ELK3 AITLWQFLLQ LLLDQK-HEH LICWTS-N-- DGEFKLLKAE EVAKLWGLRK
ELK1 SVTLWQFLLQ LLREQG-NGH IISWTSRD-- GGEFKLVDAE EVARLWGLRK
ETV3 QIQLWHFILE LLQKEE-FRH VIAWQQGE-- YGEFVIKDPD EVARLWGRRK
ETV7 CRL LWDYVYQ LLLDTR-YEP YIKWEDKD-- AKIFRVVDPN GLARLWGNHK
ETV6 CRLLWDYVYQ LLSDSR-YEN FIRWEDKE-- SKIFRIVDPN GLARLWGNHK
SPIB KLRLYQFLLG LLTRGD-MRE CVWWVEPGAG VFQFSSKHKE LLARRWGQQK
ETV2 PIQLWQFLLE LLHDGA-RSS CIRWTGNSR- --EFQLCDPK EVARLWGERK
FLI1 QIQLWQFLLE LLSDSA-NAS CITWEGTNG- --EFKMTDPD EVARRWGERK
SPIC KLRLFEYLHE SLYNPE-MAS CIQWVDKTKG IFQFVSKNKE KLAELWGKRK
ERF QIQLWHFILE LLRKEE-YQG VIAWQGD--- YGEFVIKDPD EVARLWGVRK
FEV QIQLWQFLLE LLADRAN-AG CIAWEGG--- HGEFKLTDPD EVARRWGERK
ERG QIQLWQFLLE LLSDSSN-SS CITWEGT--- NGEFKMTDPD EVARRWGERK
EHF GTHLWEFIRD ILLNPDKNPG LIKWEDRS-- EGVFRFLKSE AVAQLWGKKK
Consistency464*879865 9*36440344 494*552400 345*664656 58976**46*
-KNSNMTYEK LSRAMRYYYK REILERVD-G RRLVYKFGKN
-KNDRMTYEK LSRALRYYYK TGILERV--D RRLVYKFGKN
-NKPDMNYET MGRALRYYYQ RGILAKVE-G QRLVYQFKDM
-NKPDMNYET MGRALRYYYQ RGILAKVE-G QRLVYQFKEM
-NKPDMNYET MGRALRYYYQ RGILAKVE-G QRLVYQFKEM
-NRPAMNYDK LSRSIRQYYK KGIIRKPDIS QRLVYQFVHP
GNRKKMTYQK MARALRNYGK TGEVKKV--K KKLTYQFSGE
-NKPKMNYEK LSRGLRYYYD KNIIHKTA-G KRYVYRFVCD
-NKPKMNYEK LSRGLRYYYD KNIIHKTS-G KRYVYRFVCD
-NRPAMNYDK LSRSLRYYYE KGIMQKVA-G ERYVYKFVCD
-NRPAMNYDK LSRSLRYYYE KGIMQKVA-G ERYVYKFVCE
-NRPAMNYDK LSRSLRYYYE KGIMQKVA-G ERYVYKFVCD
-NKPNMNYDK LSRALRYYYV KNIIKKVN-G QKFVYKFVSY
-NKPTMNYEK LSRALRYYYD GDMICKVQ-G KRFVYKFVCD
-NKTNMNYDK LSRALRYYYD KNIIKKVI-G QKFVYKFVSF
-NKTNMNYDK LSRALRYYYD KNIIRKVS-G QKFVYKFVSY
-CKPQMNYDK LSRALRYYYN KRILHKTK-G KRFTYKFNFN
-NRVNMTYEK MSRALRHYYK LNIIKKEP-G QKLLFRFLKT
-NRTNMTYEK MSRALRHYYK LNIIRKEP-G QRLLFRFMKT
GNRKRMTYQK LARALRNYAK TGEIRKVK-- RKLTYQFDSA
-RKPGMNYEK LSRGLRYYYR RDIVRKSG-G RKYTYRFGGR
-SKPNMNYDK LSRALRYYYD KNIMTKVH-G KRYAYKFDFH
GNRKTMTYQK MARALRNYGR SGEITKI--R RKLTYQFSEA
-CKPQMNYDK LSRALRYYYN KRILHKTK-G KRFTYKFNFN
-SKPNMNYDK LSRALRYYYD KNIMSKVH-G KRYAYRFDFQ
-SKPNMNYDK LSRALRYYYD KNIMTKVH-G KRYAYKFDFH
-NNSSMTYEK LSRAMRYYYK REILERVD-G RRLVYKFGKN
y06754*7*78 88*89*7*85 6577496307 686697*333
Unconserved 0 1 2 3 4 5 6 7 8 9 10 Conservedb










Figure 4.10 ETV4 point mutations ablate interaction with MED25. (a) Equilibrium 
dissociation constants (KD) of ETV4 point mutants F54A and S429A with MED25 
as measured by biolayer interferometry. Values from three individual experiments 
are displayed as well as the mean and standard deviation. Two-tailed, 
heteroscedastic t-tests were used to calculate p-values between different 
fragments. The activation domain and ETS domain are abbreviated as AD and 
ED, respectively. (b) Comparison of association (ka) and dissociation (kd) rate 
constants for the interactions between ETV4 point mutants and MED25. The 
mean and standard deviation calculated from three individual experiments are 




    Table 4.2 Interaction of ETV4 point mutants with 
MED25 
 ETV4 KD (x 10-9 M)a ka (x 103 M-1s-1)a kd (x 10-3 s-1)a 
1-484 6 ± 1 300 ± 100 1.7 ± 0.2 
1-484 F54A 60 ± 10 22 ± 7 1.2 ± 0.3 
1-484 S249A 190 ± 35 500 ± 100 90 ± 10 
aMean and standard deviation from at least three individual 
experiments. 
    
    


















Figure 4.11 Interaction with MED25 activates the DNA binding of ETV4. (a) 
EMSAs with titrations of ETV4 with (top) or without (bottom) MED25 ACID 
domain. (b) KD values of ETV4 and ETS1 for DNA with (red) or without (black) 
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Abstract 
 
ETS transcription factors from the ERG and ETV1/4/5 subfamilies are 
overexpressed in the majority of prostate cancers and drive cancer progression, 
in part, by activating the expression of cell migration genes that are regulated by 
composite ETS and AP1 DNA binding sites. In contrast, EHF and SPDEF, ETS 
factors that are normally expressed in the prostate, have been characterized as 
tumor suppressors of prostate cancer and transcriptionally repress ETS-AP1 
regulated loci. Here we demonstrate that JUN-FOS displays negative 
cooperativity with EHF and SPDEF at closely spaced ETS-AP1 DNA-binding 
sites. In contrast, ERG and ETV4 are capable of binding to DNA with JUN-FOS 
without mutual interaction or with positive cooperativity, respectively. 
Furthermore, ERG binds to the nonoptimal ETS sequence characteristic of ETS-
AP1 composite sites with ~14-fold lower affinity than a consensus high affinity 
ETS sequence, whereas EHF affinity differs by a more modest ~3-fold. We 
develop a model of competing ETS factors with EHF binding to ETS-AP1 
composite sites in isolation whereas ERG binds to these sites with JUN-FOS.  
These findings provide evidence for the differential transcriptional regulation 
observed among ETS factors at ETS-AP1 composite sites. 
 
Introduction 
Multiple transcription factor (TF) binding sites in enhancers and promoters 
allow for the combinatorial control of gene transcription by integrating multiple 
inputs, such as signaling pathways, into a single transcriptional output1,2. TFs are 
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classified into families based on DNA-binding domain structure3. TFs from an 
individual family recognize similar DNA sequences4,5 and have overlapping 
expression profiles6, often resulting in a competition between multiple TFs for the 
same binding site at many genomic loci7. A neighboring, distinct TF site can 
influence this competition for DNA-binding by selecting for, or against, one of the 
competing TFs through cooperative or antagonistic DNA-binding, respectively.    
 The ETS (E26-transformation specific) family of transcription factors are 
defined by their DNA-binding domain, a winged helix-turn-helix structure termed 
the ETS domain8,9. Transcription factor partnerships with other transcription 
factors have been described for several ETS factors10-15, and these partnerships 
are specific for an individual ETS factor or subfamily of ETS factors. Therefore, 
composite DNA sites that contain an ETS site in combination with another TF 
binding site are distinctly regulated by a single or subfamily of ETS factors7,16. 
 ETS transcription factors from the ERG and ETV1/4/5 subfamilies are 
overexpressed in the majority of prostate cancers17 and contribute to the 
development of prostate cancer in mouse models of the disease18-20. In contrast, 
the ETS factors EHF and SPDEF, which are expressed in normal prostate tissue, 
have been characterized as tumor suppressors in the context of prostate 
cancer21,22. Evidence suggests that this phenotypic dichotomy of ETS factors in 
the prostate may derive, in part, from differential regulation of composite ETS 
and activator protein 1  (AP1) DNA-binding sites. Genome-wide analyses 
demonstrated that ERG and ETV1/4/5 factors bind to ETS-AP1 DNA-binding 
sites and activate the transcription of ETS-AP1 regulated genes that are 
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important for processes such as cell migration23. In contrast, EHF and SPDEF 
have been shown to transcriptionally repress particular ETS–AP1 regulated 
genes23,24. ERG and ETV1/4/5 factors have been shown to cooperatively bind to 
DNA with JUN-FOS25, suggesting that differences in cooperative DNA-binding 
may distinguish between ETS factors at ETS-AP1 sites. It is currently unknown 
how EHF or SPDEF affect JUN-FOS activity at ETS-AP1 tandem DNA sites.     
 Here we demonstrate a differential ability of ETS factors to bind to DNA 
with JUN-FOS. Using the previously characterized uridine phosphorylase gene 
promoter (UPP), we find that ETS factors can either display negative 
cooperativity (EHF and SPDEF), or positive cooperativity (ERG and FLI1) with 
JUN-FOS on ETS-AP1 composite DNA sites. In addition, ETV1 and ETV4 bind 
together with JUN-FOS and have no influence on the affinity of DNA-binding. 
Interestingly, we find that EHF has a stronger affinity for the nonoptimal –
AGGAA- ETS motif that occurs within ETS-AP1 motifs than ERG. These 
differences in affinity map to the ETS domain and are likely due to sequence 
divergence of amino acids that contact DNA. Furthermore, we discover that the 
features of EHF required for DNA-binding antagonism with JUN-FOS reside 
outside of the ETS domain. In summary, this study establishes the differences in 
binding to ETS-AP1 consensus sites and in cooperation with JUN-FOS between 
distinct ETS factors and provides a biochemical basis for alternative functionality 
of ETS factors in prostate cancer.  
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Results 
JUN-FOS differentially affects ETS factor binding to  
composite ETS-AP1 sites 
The promoter for the uridine phosphorylase gene (UPP) contains a 
composite ETS-AP1 DNA motif. We used electrophoretic mobility shift assays 
(EMSAs) to determine the equilibrium dissociation constants (KD) of ETS factors 
for the UPP promoter in the presence or absence of saturating JUN-FOS. We 
titrated the ETS factors EHF, SPDEF, ETV1, ETV4, ERG, and FLI1 with the UPP 
promoter alone, and with JUN-FOS bound to DNA (Fig. 5.1). EHF and SPDEF 
had relatively tighter binding (lower KD values) for the UPP DNA compared to the 
other ETS factors, with values varying up to ~10-fold between ETS factors. 
Additionally, JUN-FOS strongly deterred the binding of EHF (~30-fold) and 
SPDEF (~20-fold) (Figs. 5.1 and 5.2). In comparison, ETV1 and ETV4 bound 
with about the same affinity with or without JUN-FOS, and ERG (~5-fold) and 
FLI1 (~20-fold) bound more strongly with JUN-FOS, as previously suggested25. 
These results demonstrate that ETS factors respond differently to the presence 
of JUN-FOS in a composite ETS-AP1 DNA site with ERG and FLI1, ETV1 and 
ETV4, and EHF and SPDEF displaying cooperative, noncooperative, and anti-
cooperative DNA-binding with JUN-FOS, respectively. 
 
DNA determinants of ETS-AP1 DNA binding 
We were surprised by the substantial difference in the affinity of ETS 
factors for the UPP DNA in the absence of JUN-FOS, so we next probed the 
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basis of this variance. The consensus high-affinity DNA site for all of these ETS 
factors is -CCGGAAGT-, with the exception that SPDEF shows an equal 
preference for A and T at the sixth nucleotide (-CCGGAAGT- and –CCGGATGT-
)4,26. There is only a single C to A difference between the consensus high-affinity 
ETS site and the ETS site observed in composite ETS-AP1 sites (-CAGGAAGT-
), and this change occurs outside of the -GGAA- core of the ETS binding site23. 
While EHF and SPDEF belong to a different DNA-binding subclass of ETS 
factors than the other ETS factors tested here, previous findings suggest that all 
of these ETS factors have a similar preference for C over A at this position4. EHF 
and ERG both bound to consensus high-affinity ETS sites (-CCGGAAGT-) with 
similar KD values of 1.0 ± 0.1 and 0.7 ± 0.2 nM, respectively (Fig. 5.3). 
Incorporating the single C to A change (-CAGGAAGT-) into the ETS site resulted 
in decreased affinity of all ETS factors for the DNA. However, the difference was 
only ~ 3-fold for EHF (1.0 ± 0.1 versus 2.9 ± 0.5 nM), whereas it was ~ 14-fold for 
ERG (0.7 ± 0.2 versus 10 ± 5 nM). Furthermore, both EHF and ERG bound to an 
ETS-AP1 composite site with similar affinity as the high affinity ETS site with the 
C to A change. Therefore, while the single C to A change decreases affinity for 
all ETS factors tested here, it has a stronger effect on ERG. Therefore, in the 
absence of JUN-FOS, EHF binds with higher affinity to ETS-AP1 sites than ERG. 
 Although all ETS-AP1 composite sites have a nonoptimal ETS-binding 
sequence, ETS-AP1 composite sites display variable spacing between the ETS 
and AP1 binding sequences23. Following previous nomenclature, the most 
common spacing is +6 base-pairs (bp), which corresponds to –
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AGGAAGTGAXTCA- with the core ETS and AP1 binding sequences underlined, 
and X referring to any nucleotide (Fig. 5.4). However, other spacing is frequently 
observed for ETS-AP1 composite sites. This is in contrast to ETS-RUNX 
composite DNA sites that have a singular dominant spacing between ETS and 
RUNX binding sequences16.   
We next investigated how the variable spacing of ETS and AP1 
sequences influences the binding of JUN-FOS and ETS factors to these 
composite sites. With 6 bp spacing between ETS and AP1 DNA binding sites, we 
again observed that JUN-FOS strongly deters the binding of EHF (Fig. 5.5a-b). 
However, 11, 16, or 22 bp spacing accommodates the binding of both EHF and 
JUN-FOS, and EHF binds to both free DNA and DNA with JUN-FOS bound with 
similar KD values. In contrast, ERG can bind to DNA with JUN-FOS on all of the 
DNA spacing options that were tested (Fig. 5.5c-d). These data suggest that the 
difference between EHF and ERG in binding to DNA with JUN-FOS is limited to 
composite sites with less than 11 bp between ETS and AP1 DNA-binding motifs.  
Given the strong antagonism displayed by JUN-FOS towards EHF binding 
at a composite ETS-AP1 DNA site with 6-bp spacing, we next investigated the 
reciprocality of this relationship. The presence of EHF had no detectable impact 
on JUN-FOS binding to composite sites with the more distal 11, 16, and 22 bp 
DNA spacing.  Furthermore, we observed slower mobility bands corresponding to 
co-occupancy of EHF and JUN-FOS on the DNA (Figs. 5.6 and 5.7). At 
composite sites with 6-bp spacing of DNA, EHF antagonized JUN-FOS by only a 
modest 2-fold, compared to the ~100-fold decrease that was observed for EHF 
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binding. Slower mobility bands are not observed, as was the case with the 
reciprocal experiment (Fig. 5.5 a-b), indicating that JUN-FOS efficiently replaces 
EHF on the DNA. Interestingly, these results suggest nonreciprocal cooperativity 
in which JUN-FOS robustly deterred EHF from binding to DNA at the 6-bp 
composite sites whereas EHF only weakly deterred JUN-FOS binding. Previous 
studies have demonstrated that the dissociation rate constant for JUN-FOS is 
relatively smaller (slower dissociation rates) compared to ETS factors25. 
Therefore, while the equilibrium dissociation constants of JUN-FOS and EHF are 
relatively similar, this difference in the kinetics of interaction with DNA may 
underlie the nonreciprocal nature of antagonizing DNA binding between EHF and 
JUN-FOS. 
 
DNA-binding domains (DBDs) of EHF and JUN-FOS  
are not sufficient for antagonism of DNA binding 
The close proximity required for antagonistic DNA binding between EHF 
and JUN-FOS suggested that the features required for JUN-FOS antagonizing 
the DNA binding of EHF might be located near the (DBDs) of these factors. We 
devised a rough structural model of the DBDs of these factors using DNA-bound 
structures of the ETS domain from ERG27 (4IRI.pdb) or ELF328 (3JTG.pdb), the 
closest paralog of EHF with a solved structure for the ETS domain, and the bZIP 
domains of JUN-FOS29 (1FOS.pdb) (Fig. 5.8). These structures were aligned on 
a modeled 6-bp composite motif. This model suggests that the ETS domain from 
both ERG and EHF can bind DNA with JUN-FOS without any steric hindrance. 
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However, the inability of full-length EHF to bind to this site indicates two 
possibilities. Either our model does not accurately reflect the DNA-bound state of 
ETS and JUN-FOS factors, or a region outside of the ETS domain of EHF is 
necessary for the antagonism of EHF and JUN-FOS.  
 To test the whether the DBDs of EHF and JUN-FOS are sufficient for 
DNA-binding antagonism, we expressed and purified fragments corresponding to 
the ETS domain of EHF (amino acids 203-300) and the bZIP domains of JUN 
(amino acids 250-319) and FOS (amino acids 131-203). After purification we 
combined JUN and FOS DBDs at a 1:2 molar ratio and this heterodimer bound to 
DNA with much stronger affinity (KD = 1.2 nM) than JUN (KD = 40 nM) or FOS 
homodimers (KD too high to be determined) (Fig. 5.9). EHF and JUN-FOS DBDs 
bound to the 6-bp composite ETS – AP1 site with similar affinity as full-length 
EHF and JUN-FOS, respectively (Fig. 5.10). Interestingly, the DBD of EHF is 
able to bind to the 6-bp composite ETS – AP1 DNA site with the DBD of JUN-
FOS (Fig. 5.11a). In contrast, full-length EHF displaces JUN-FOS DBD (Fig. 
5.11b), as previously observed with full-length JUN-FOS. We conclude that the 
ETS domain of EHF can bind to DNA with the bZIP domains of JUN-FOS, 
indicating that a region outside of the ETS domain of EHF is required for 
antagonizing activity of JUN-FOS. There is a band of minor intensity with slower 
mobility than the full-length EHF:DNA band. This band might correspond to full-
length EHF and JUN-FOS DBD co-occupying a single DNA duplex. In this case, 
components outside of both DBDs of both ETS and AP1 factors contribute to 
DNA-binding antagonism. 
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Discussion        
Here we have shown that ETS factors have contrasting abilities to bind to 
composite ETS-AP1 sites. The two components that contribute to differential 
binding by ETS factors to ETS-AP1 sites are (i) differing affinities between ETS 
factors for the modified ETS site that is characteristic of ETS-AP1 composite 
motifs and (ii) distinct capabilities between ETS factors for binding to these 
composite motifs with JUN-FOS. Whereas EHF strongly binds to ETS-AP1 
composite sites, its binding is antagonistic to simultaneous JUN-FOS binding. In 
contrast, ERG weakly binds to ETS-AP1 composite sites, but can bind to DNA in 
conjunction with JUN-FOS. The difference in affinity for the ETS-AP1 composite 
motif maps to the ETS domains of ERG and EHF, thus implicating divergent 
sequences that contact DNA (Fig. 5.12). However, the ETS domain of EHF is not 
sufficient for the anticooperative DNA-binding with JUN-FOS. Thus, we 
hypothesize that the region just N terminal of the ETS domain is responsible for 
this effect based on two lines of evidence. First, we observe anticooperative 
binding between EHF and JUN-FOS with 6-bp spacing but not with 11-bp or 
greater spacing between the two sequences, indicating that the region of EHF 
responsible for antagonism is proximally located, at least in three-dimensional 
space, to the ETS domain. Second, our structural model demonstrates that with 
the 6-bp spacing the N terminus of the ETS domain is oriented towards, and in 
close proximity to (~ 3 Å) JUN-FOS. This hypothesis is also consistent with 
observations of a fragment of SPI1 containing the ETS domain with an additional 
15 amino acids N-terminal and 5 amino acids C-terminal that also anti-
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cooperatively binds to DNA with JUN-FOS25. The sequences just N-terminal of 
the ETS domain are not conserved between SPI1 and EHF; however, both 
factors contain stretches of positive residues, KKK for SPI1 and KKH for EHF, 
that are evolutionarily conserved for each factor (Fig. 5.12). We hypothesize that 
these positive residues may result in charge repulsion with the highly basic DBDs 
of JUN and FOS. Further experiments that would disrupt these residues or 
structural studies that would define the interaction will be necessary to test this 
hypothesis. In summary, differences sequences within and outside of the ETS 
domain for EHF and ERG underlie the differential ability of these factors to bind 
to ETS-AP1 motifs and cooperatively bind to DNA with JUN-FOS.    
The RAS/RAF/MEK/ERK (RAS-MAPK) signaling pathway amplifies the 
transcription output of ERG and ETV1/4/5 factors, as well as JUN-FOS, but not 
EHF or SPDEF30-32. Transcriptional activation in response to RAS-MAPK 
signaling is a common feature of many ETS factors, including several that are 
expressed in normal prostate tissue such as ETS1 and GABPA. Interestingly, 
among other ETS factors that are transcriptionally activated by RAS-MAPK 
signaling, all, except SPIB, belong to the same DNA-binding subclass as ERG 
and ETV44. This suggests that, similarly to ERG, these RAS-MAPK-responsive 
ETS factors would also bind more poorly to the –AGGAA- ETS motif in ETS-AP1 
consensus sites. Therefore, ETS sites within the composite ETS-AP1 motifs 
appear “suboptimized”33 in that they favor binding by the ETS factors, such as 
EHF and SPDEF, which do not amplify transcriptional output in response to RAS-
MAPK signaling. Additionally, EHF and SPDEF compete with the other factors at 
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that site, ERG, ETV4, and JUN-FOS, which are capable of amplifying 
transcriptional output in response to RAS-MAPK signaling. This competition likely 
dampens the transcription of ETS-AP1 regulated genes in the normal prostate23 
(Fig. 5.13). However, common genetic lesions in prostate cancer, such as the 
loss of EHF34 or SPDEF22, and/or the overexpression of ERG or ETV1/4/5 
factors17, would perturb this hypothesized competition resulting in the 
overexpression genes that are important for cellular migration, a hallmark of the 
invasive stage of oncogenesis promoted by ETS factors23.  
   
Methods 
Expression plasmids 
Human ETS and JUN-FOS cDNAs corresponding to full-length or 
truncated proteins were cloned into the bacterial expression vector pET28 
(Novagen) using standard sequence- and ligation-independent cloning 
strategies35. 
 
Expression and purification of proteins 
All proteins were produced in Escherichia coli (lDE3) cells. Minimal DNA-
binding domains for ETS and JUN-FOS proteins were efficiently expressed into 
the soluble fraction. Cultures of 1 L Luria broth (LB) were grown at 37 °C to 
OD600 ~ 0.7 – 0.9, induced with 0.5 mM isopropyl-b-D-thiogalactopyranoside 
(IPTG), and grown at 30 °C for ~ 3 hours.  
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Harvested cells were resuspended in 25 mM Tris pH 7.9, 1 M NaCl, 5 mM 
imidazole, 0.1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM 2-
mercaptoethanol (BME) (5 mM BME for JUN-FOS DBDs), and 1 mM 
phenylmethanesulfonylfluoride (PMSF). Cells were lysed by sonication and 
centrifuged at 40k rpm in a 45 Ti rotor (Beckman) for at least 30 minutes at 4 °C. 
After centrifugation, the soluble supernatants were loaded onto a Ni2+ affinity 
column (GE Biosciences) and eluted over a 5 – 500 mM imidazole gradient. 
Fractions containing purified ETS protein were pooled, combined with ~ 1 U 
thrombin / mg of purified protein, and dialyzed overnight at 4 °C into 25 mM Tris 
pH 7.9, 10% glycerol (v:v), 1 mM EDTA, 50 mM KCl, and 1 mM dithiothreitol 
(DTT). 10 mM DTT and 10% glycerol (v:v) was added to JUN and FOS DBDs 
which were then flash frozen in single-use aliquots for EMSAs.  After 
centrifugation at 40k rpm for 30 minutes at 4 °C, the soluble fraction was loaded 
onto a SP-sepharose cation exchange column (GE Biosciences) and eluted over 
a 50 – 1000 mM KCl gradient. Fractions containing the ETS proteins were loaded 
onto a Superdex 75 gel filtration column (GE Biosciences) in 25 mM Tris pH 7.9, 
10% glycerol (v:v), 1 mM EDTA, 300 mM KCl, and 1 mM DTT. Eluted fractions 
were analyzed by SDS-PAGE. The final, purified protein was then concentrated 
on a 3-kDa molecular weight cut-off (MWCO) Centricon device, snap-frozen with 
liquid nitrogen, and stored at -80 °C in single-use aliquots for subsequent EMSA 
studies.  
Full-length ETS and JUN-FOS factors generally expressed more efficiently 
in the insoluble fraction (with the exception of EHF which was expressed and 
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purified as described above) using either an IPTG expression protocol as 
described above or an “auto-induction” protocol36. Briefly, bacteria in 250 mL of 
autoinduction media were grown in 4 L flasks at 37 °C to an OD600 ~ 0.6 – 1. The 
temperature was then reduced to 30 °C and cultures were grown for another ~ 
12 – 24 hours. Final OD600 values were typically ~ 6 – 12, indicating robust 
autoinduction. Harvested cells were resuspended as described above, sonicated 
and centrifuged at 15k rpm in a JA-17 rotor (Beckman) for 15 minutes at 4 °C. 
The soluble fraction was discarded and this procedure was repeated with the 
pellet / insoluble fraction twice more to rinse the inclusion bodies. The final 
insoluble fraction was resuspended with 25 mM Tris pH 7.9, 1 M NaCl, 0.1 mM 
EDTA, 5 mM imidazole, 2 mM BME, 1 mM PMSF, and 6 M urea. After sonication 
and incubation for ~ 1 hour at 4 °C, the sample was centrifuged for 40k rpm for at 
least 30 minutes at 4 °C. The soluble fraction was loaded onto a Ni2+ affinity 
column (GE Biosciences) and refolded by immediately switching to a buffer with 
the same components as above, except lacking urea. After elution with 5 – 500 
mM imidazole, the remaining purification steps using ion-exchange and size-
exclusion chromatography were performed as described above. HIS6-tagged 
FOS and untagged JUN were combined prior to Ni2+ column purification to enrich 
for a molar excess of FOS. JUN-FOS heterodimers were then purified with size-
exclusion column but not ion-exchange column. Thrombin cleavage of His6-tags 
was not used on FL ETS and JUN-FOS factors due to internal cleavage sites for 
some proteins. Also, either a Q-sepharose anion-exchange column or a SP-
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sepharose cation-exchange column was used depending on the isoelectric point 
of the protein. 
 
 Electrophoretic mobility shift assays (EMSAs) 
DNA-binding assays utilized the following duplexed oligonucleotides: 
UPP promoter  
5’-TAGGGGAAATGACTCATTCA-3’ 
5’-TGAATGAGTCATTTCCCCTA-3’  
High Affinity ETS consensus 
5’-TCGACGGCCAAGCCGGAAGTGAGTGCC-3  
5’-TCGAGGCACTCACTTCCGGCTTGGCCG-3’;  
High Affinity ETS consensus C2A 
5’-TCGACGGCCAAGCAGGAAGTGAGTGCC-3  
5’-TCGAGGCACTCACTTCCTGCTTGGCCG-3’;  
ETS-AP1 6 bp spacing 
 5’-TCGACGGCCAAGCAGGAAGTGACTCAGCCCGATCG-3’  
5’-TCGACGATCGGGCTGAGTCACTTCCTGCTTGGCCG-3’;  
ETS-AP1 11 bp spacing 
5’-TCGACGGCCAAGCAGGAAGTAAAGTGACTCAGCCCGATCG-3’ 
5’-TCGACGATCGGGCTGAGTCACTTTACTTCCTGCTTGGCCG-3’  
ETS-AP1 16 bp spacing  
5’-TCGACGGCCAAGCAGGAAGTACGTACAAGTGACTCAGCCCGATCG-3’  
5’-TCGACGATCGGGCTGAGTCACTTGTACGTACTTCCTGCTTGGCCG-3’  
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Boldface GGAA and TGACTCA indicate the ETS and AP1 binding site motifs, 
respectively. Each of these oligonucleotides, at 2 µM as measured by 
absorbance at 260 nM on a NanoDrop 1000 (Thermo Scientific), were labeled 
with [g-32P] ATP using T4 polynucleotide kinase at 37 °C for ~ 30 – 60 minutes. 
After purification over a Bio-Spin 6 chromatography column (Bio-Rad), the 
oligonucleotides were incubated at 100 °C for ~ 5 minutes, and then cooled to 
room temperature over 1 – 2 hours. The DNA for EMSAs was diluted to 1 x 10-12 
M and held constant, whereas protein concentrations ranged ~ 6 orders of 
magnitude with the exact concentrations dependent on the KD of particular 
protein fragments. Protein concentrations were determined after thawing each 
aliquot of protein, using the Protein Assay Dye Reagent. Equivalent starting 
amounts (0.2 mg) of each protein utilized on a given day were run on an SDS-
PAGE gel to confirm their relative concentrations. The binding reactions were 
incubated for 45 minutes at room temperature in a buffer containing 25 mM Tris 
pH 7.9, 0.1 mM EDTA, 60 mM KCl, 6 mM MgCl2, 200 mg/mL BSA, 10 mM DTT, 
2.5 ng/mL poly(dIdC), and 10% (v:v) glycerol, and then resolved on an 8% (w:v) 
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native polyacrylamide gel at room temperature. The 32P-labeled DNA was 
quantified on dried gels by phosphorimaging on a Typhoon Trio Variable Mode 
Imager (Amersham Biosciences). Equilibrium dissociation constants (KD) were 
determined by nonlinear least squares fitting of the total protein concentration [P]t 
versus the fraction of DNA bound ([PD]/[D]t) to the equation [PD]/[D]t = 1/[1 + 
KD/[P]t)] using Kaleidagraph (v. 3.51; Synergy Software). Due to the low 
concentration of total DNA, [D]t, in all reactions, the total protein concentration is 
a valid approximation of the free, unbound protein concentration. Reported KD 
values represent the mean of at least three independent experiments and the 
standard error of the mean. 
 
Structural modeling 
Structural modeling was performed using PyMol (Schrödinger, LLC). DNA-
bound structures of JUN-FOS29 (1FOS.pdb), ERG27 (4IRI.pdb), or ELF328 
(3JTG.pdb) were aligned using DNA sequences that would overlap in a 
composite ETS-AP1 motif with 6 bp DNA spacing: 4IRI/B nucleotides 9-12 and 











Figure 5.1 JUN-FOS differentially influences the DNA binding of ETS factors. (a) 
Representative EMSAs for EHF (left), ETV4 (middle), and FLI1 (right), to the 
UPP promoter DNA duplex. Note that higher band for EHF corresponds to two 
EHF molecules bound to the DNA duplex, as previously observed25. (b) As in (a), 
but with JUN-FOS bound to DNA duplex. (c) Quantification of cooperativity with 
JUN-FOS, where cooperativity = KD (ETS only) / KD (ETS + JUN-FOS). See Fig. 


















Figure 5.2 JUN-FOS differentially influences the DNA binding of ETS factors. 
Binding isotherms for ETS factors binding to DNA bearing the sequence of the 
UPP promoter in the absence (black) or presence of JUN-FOS (gray). Each data 
point is the mean from two replicates. See Methods for details. 
 
  





Figure 5.3 Single-nucleotide change in ETS binding sequence differentially 
affects the DNA binding of ETS factors. (a) Top strand of DNA duplexes used for 
measuring KD values with EHF or ERG. ETS and AP1 DNA-binding sites are 
underlined. Binding isotherms for EHF (b) and ERG (c) with the DNA duplex 
containing a consensus DNA sequence for these factors (black), a single 
nucleotide change (dark gray) that occurs at ETS-AP1 composite motifs, or an 
ETS-AP1 composite site (light gray) with a DNA spacing of 6 bp between ETS 
and AP1 binding sequences. Mean and standard error of the mean are displayed 
from at least three replicates. (d) Comparison of KD values for EHF and ERG for 
all three DNA duplexes. Each dot depicts a single replicate and lines depict the 
mean and standard deviation for each group of replicates. Two-tailed 
heteroscedastic t-tests were used to calculate p values. 
 
 

















Figure 5.4 Spacing of in vivo ETS and AP1 binding sequences. Frequency of 
occurrence for each given spacing between ETS and JF binding sequences. 
Data derived from MEME analysis of ERG occupied genomic regions23. Gray line 
is the frequency smoothed over a 6bp window. Data are modified from 



































Figure 5.5 Spacing dependence of JUN-FOS (J-F) antagonism of EHF binding. 
Representative EMSAs. The variable bp spacing at top refers to DNA length 
between ETS and AP1 DNA binding sites. First three lanes of each EMSA are 
controls with DNA only, ETS:DNA, and JUN-FOS:DNA, respectively. Triangle 
denotes a titration with an increasing amount of ETS factor. EHF alone (a) and 
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Figure 5.6 Spacing dependence of EHF antagonism of JUN-FOS binding. 
Binding isotherms for JUN-FOS alone (black) or with EHF (gray) for DNA 
duplexes with spacing of 6 (a), 11 (b), 16 (c), or 22 bp (d) between ETS and 
JUN-FOS DNA-binding sites. See Fig. 5.7 for representative EMSAs. (e) 
Cooperativity of JUN-FOS DNA-binding with EHF as a function of DNA spacing. 
Cooperativity = KD (JUN-FOS) / KD (JUN-FOS with EHF). Mean and standard 
error of the mean are displayed for three replicates. 


















Figure 5.7 EHF effects on JUN-FOS binding. Representative EMSAs with DNA 
sequence with spacing between ETS and AP1 sites as displayed above EMSAs. 
First three lanes of each EMSA are controls with DNA only, ETS:DNA, and JUN-
FOS:DNA, respectively. Triangle denotes a titration with an increasing amount of 
JUN-FOS. (a) EMSAs for JUN-FOS. (b) EMSAs for JUN-FOS with EHF bound to 

















Figure 5.8 Structural model for ETS and AP1 factors bound to DNA. (a) 
Structures of ERG (4IRI.pdb)27 and JUN-FOS (1FOS.pdb)29 bound to DNA were 
aligned to assemble a composite DNA site and ternary complex. See Methods 
for details. (b) As in (a) but with mouse ELF3 (3JTG.pdb)28, a closely related 
paralog of EHF. The JUN-FOS heterodimer can bind to consensus palindromic 
DNA sequences in either orientation29, so the relative positioning of JUN and 
FOS relative to ETS factors in this model is arbitrary.  The alternative orientations 

















Figure 5.9 DNA binding affinities of JUN-FOS heterodimer, JUN or FOS 
homodimers. Representative EMSAs. Equivalent titrations of JUN-FOS 
heterodimer (mixed at a 1:2 JUN:FOS molar ratio, top) and JUN (middle) or FOS 
(bottom) homodimers. Dimers were assembled with DBDs of JUN (amino acids 




























Figure 5.10 DBDs and full-length EHF and JUN-FOS bind to ETS-AP1 
composite site with similar affinity. Binding isotherms for EHF full length (gray) 




















Figure 5.11 The DBDs of EHF and JUN-FOS can simultaneously bind ETS – 
AP1 composite DNA sites with 6-bp spacing. Representative EMSAs with the 
first three lanes of each EMSA being DNA only, EHF:DNA, and JUN-FOS:DNA 
controls, respectively. Triangle denotes a titration with an increasing amount of 
EHF. (a) ETS domain of EHF, amino acids 203-300, was titrated in absence 
(top), or presence of the JUN-FOS DBDs (bottom). (b) Full-length EHF, amino 


















Figure 5.12 Sequence conservation of ETS domain and flanking regions for 
selected ETS factors. Sequences are aligned for ETS factors that do (below 
dotted line) or do not (above dotted line) display anticooperativity in binding with 
JUN-FOS to DNA with 6 bp spacing between factor binding sites using Clustal 
Omega37. Amino acids are colored according to physicochemical properties. Red 
rectangles and arrows above a sequence represent α-helices and β-strands, 
respectively. Arrows below the sequence denote amino acids that contact DNA in 
the DNA-bound structures of SPI18, SPDEF26, ERG27, or ETV138 Amino acids 
with clear differences between ETS factors that do or do not display anti-
















Figure 5.13 Model for EHF/SPDEF repression of ETS-AP1 regulated genes. (a) 
EHF / SPDEF, denoted here as EHF for simplicity, compete with other ETS 
factors for binding to ETS-AP1 binding sites in normal prostate cells. EHF binds 
more strongly to these sites than the other RAS-MAPK responsive ETS factors, 
depicted here as phosphorylated ETS1, and antagonizes the DNA-binding of 
JUN-FOS, in order to repress the transcriptional activation of ETS-AP1 regulated 
genes. (b) The addition/expression of ERG or ETV1/4/5 subfamily factors and/or 
the loss of EHF/SPDEF in prostate cancer promotes the expression of ETS-AP1 
regulated genes by perturbing the balance between RAS-MAPK responsive 
factors that can bind to DNA with JUN-FOS and RAS-MAPK irresponsive factors 
that antagonize JUN-FOS DNA binding. The spacing between ETS and JUN-
FOS binding sequences is exaggerated and not to scale in order to incorporate 
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Summary 
Here we have described distinct intra- and intermolecular protein-protein 
interactions that distinguish between ETS transcription factors that serve as 
oncoproteins and tumor suppressors in the context of prostate cancer. The DNA-
binding of ETV1, ETV4, and ETV5 is autoinhibited through proposed 
intramolecular interactions between two inhibitory regions and the ETS domain 
(Chapter 3). Less autoinhibition is observed for ERG and FLI1, and no 
autoinhibition is observed for EHF (Chapter 5). Mediator subunit 25 interacts with 
the activation domain and DNA-binding domain of ETV4, but does not interact 
with EHF (Chapter 4). EHF, but not ERG or ETV4, antagonizes the DNA binding 
of JUN-FOS (Chapter 5). Future studies will determine if these distinctions 
underlie the differential roles observed for ETS factors in prostate cancer. 
 In analyzing the ETS factors that act as oncoproteins in prostate cancer, 
we determined that ETV1, ETV4, and ETV5 have higher magnitudes of DNA-
binding autoinhibition than did ERG or FLI1 (Chapter 3). Work published during 
our investigations confirmed this lower magnitude of autoinhibition for ERG1. 
Previous studies had qualitatively observed DNA-binding autoinhibition in the 
ETS subfamily of ETV1, ETV4, and ETV5, but mechanistic detail of this inhibition 
was not interrogated2-4. We found that an intrinsically disordered region and an 
α-helix cooperatively inhibit the ETS domain by perturbing the DNA-recognition 
α-helix. Acetylation of lysine residues within the disordered region abrogated 
autoinhibition, providing one potential cellular mechanism for the regulation of 
DNA binding by ETV1, ETV4, and ETV5. The inhibitory domains are distinct from 
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those previously described for ETS15,6 or ETV67,8. Partnerships with the 
transcription factors RUNX19 and PAX510 relieve the autoinhibition of ETS1. 
Therefore, distinct protein partnerships may relieve the autoinhibition of the 
ETV1/4/5 subclass of ETS factors. 
 We analyzed whether the interaction with MED25 relieves the DNA-
binding autoinhibition of ETV4 (Chapter 4). Previous studies established that the 
N-terminal activation domain (AD) of ETV5 was sufficient for interaction with the 
activator-interacting domain (ACID) of MED2511. However, we surmised and 
subsequently discovered a secondary binding site consisting of the ETS domain 
and inhibitory α-helix of ETV4. Our findings have some similarity to the previously 
characterized bipartite interaction between the viral protein VP16 and 
MED2512,13. Mutation of residues within the inhibitory α-helix strongly ablated the 
interaction of ETV4 with MED25. The inhibitory α-helix is specific to the ETV1/4/5 
subfamily of ETS factors, providing a rationale for the specificity of MED25 
interacting with ETV4 but not EHF or ETS1. Interaction with MED25 activated the 
DNA binding of ETV4, likely by disrupting the interaction between the inhibitory 
α-helix and the ETS domain of ETV4.  
 A previous study demonstrated that ERG, ETV1, and ETV4 bind to 
composite ETS-AP1 DNA binding sites when overexpressed in prostate cells14. 
Therefore, we asked whether binding nearby with JUN-FOS relieves ETV4 
autoinhibition (Chapter 5). While we did not find evidence for modulation of ETV4 
autoinhibition, we did observe that ERG and ETV4 bind to ETS-AP1 sites with 
JUN-FOS. In contrast, EHF and SPDEF antagonize JUN-FOS binding to DNA. 
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Additionally, the nonoptimal ETS motif that occurs in the composite ETS-AP1 
DNA sites differentially disfavors ERG binding compared to EHF. These two 
findings suggest alternative scenarios whereby either EHF or SPDEF bind in 
isolation or ERG/ETV4 and JUN-FOS bind jointly to composite ETS-AP1 sites. 
This model is in agreement with the transcriptionally repressive effect of SPDEF 
and EHF on genes regulated by composite ETS-AP1 sites14,15.  
 We generated assays for ETS1 binding to DNA that are amenable to high-
throughput screening for small-molecule inhibitors of this interaction (Chapter 2). 
While we performed our limited small-molecule screens with ETS1, we also 
demonstrated that other ETS factors, such as ERG and ETV1/4/5 subfamily 
factors, could be utilized in these assays. Using a nonoptimal ETS motif in the 
DNA sequence increased the inhibition of our lead compounds in these assays. 
Interestingly, the nonoptimal ETS motif used in the screening assay is similar to 
the ETS motif in ETS-AP1 composite sites. Therefore, in addition to potentiating 
inhibitors in this assay, the use of nonoptimal ETS motifs such as the ETS-AP1 
composite site may also represent a more desirable molecular target.    
 
Future directions 
Further definition and affinity maturation of the  
minimal inhibitory element in ETV4 NID 
We broadly defined the N-terminal inhibitory domain (NID) as amino acids 
165-336 in ETV4 and demonstrated that acetylation of two lysine residues within 
the NID as relieves the autoinhibition of ETV4. However, we have not yet defined 
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the amino acids within the NID that confer inhibition on the ETS domain. 
Definition of a minimal inhibitory unit would further our understanding of 
mechanism of NID-mediated autoinhibition in ETV4.  
Additional experiments not described in Chapter 3 have contributed to our 
understanding of NID-mediated autoinhibition of ETV4. Further truncations 
suggested that amino acids 165-202 and 288-336 are dispensable for the NID’s 
inhibitory function narrowing the essential region to 203-288 (data not shown). 
Both lysine residues that relieve autoinihbition upon acetylation, 226 and 260, 
reside within this region. However, these studies are difficult to perform due to 
the unpredictable stability of truncated proteins and the relatively low level of 
magnitude of autoinhibition. For example, the dramatic instability of ETV4 246-
436 precludes accurate measurement of this fragment’s affinity for DNA. We 
would predict from our truncation studies that the complete ablation of NID-
mediated autoinhibition would result in a  ~6-fold activation. We observe three- 
and 2-fold activation from the acetylation of lysines 226 and 260, respectively, 
suggesting that multiple regions within the NID contribute to the autoinhibition of 
ETV4 (Fig. 6.1a). These regions show some resemblance to one another in their 
conservation of hydrophobic amino acids around the acetylated lysine residues. 
One method that may potentially simplify the interrogation of the molecular 
interactions that mediate ETV4 autoinhibition would be to artificially add single or 
multiple copies of the conserved region around lysine 226 to the ETS domain of 
ETV4 (Fig. 6.1b). If this minimal region around lysine 226 truly encompasses the 
single ‘unit’ of autoinhibition within the NID, we would expect to see higher levels 
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of autoinhibition with more repeating copies of the unit16. This would then provide 
a more robust assay to test the functional importance of individual amino acids in 
the NID-ETS domain interaction. Charge-reversal mutations in the NID (lysines 
226 and 260 to glutamic acid) and the ETS domain (glutamic acids 404, 423, and 
425) do not ablate autoinhibition. Therefore, my current hypothesis is that 
aromatic residues surrounding lysines 226 and 260 interact with tyrosines 401 
and 403 of the DNA-recognition α-helix in the ETS domain through π-π stacking 
interactions. These tyrosines are conserved in most (23/28) human ETS factors, 
but are both not conserved in the SPI1 subfamily. Mutation of these tyrosines to 
asparagine and glycine, the corresponding amino acids in SPI1, would test their 
role in DNA-binding autoinhibition.  
 Definition of the minimal “unit” of the NID would allow for engineering 
enhanced affinity and specificity of the NID for the ETS domain of ETV4 - a 
process termed affinity maturation17. The development of an inhibitory peptide 
with increased affinity and specificity for the ETS domain of ETV4 could serve as 
a tool to understand the consequences of dampening the function of ETV4 in 
prostate cancer and could serve as a basis for designing a small-molecule 
inhibitor18. We estimate that the separated NID (amino acids 165-336) and CID-
inhibited ETV4 fragment (amino acids 337-436) interact in trans with an 
equilibrium dissociation constant, KD, of ~ 40 mM based on biolayer 
interferometry experiments (data not shown). Truncation to a minimal inhibitory 
unit of ~20 amino acids would allow for saturating mutagenesis with either 
phage19 or yeast20 surface display using interaction with the CID-inhibited 
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fragment of ETV4 as the selection (Fig. 6.1c). While there is a high likelihood of 
substantially increasing the affinity of the NID-ETS interaction of ETV4 with this 
method, the more challenging task would be to specifically increase the affinity of 
the NID interaction with the ETS domain of ETV4, while generating or retaining 
specificity compared to other ETS domains. For example, the ETS domain of 
EHF could be used as a control to search for matured peptides that bind with 
high affinity to ETV4, but not to EHF. Such a peptide would meet the goal of 
development of a tool for studying the specific biological roles of ETV4. 
Additionally, structural understanding of the interaction between the inhibitory 
peptide and the ETS domain of ETV4 would guide future site-directed chemical 
screens to search for a specific small-molecule inhibitor21.  
 
Determining the importance of the ETV4 - MED25  
interaction in prostate cancer 
Previously, ETV4 has been shown to promote the metastasis of prostate 
cancer in response to activated PI3-kinase and Ras signaling in a mouse model 
of prostate cancer22. The overexpression of ETV4 in normal prostate cell lines is 
also sufficient to induce anchorage-independent growth22,23 and cell migration14. 
Therefore, both simple cell line models and whole organism mouse models exist 
and can be used to test the importance of the ETV4-MED25 interaction in 
prostate cancer. For example, wild-type ETV4 could be compared to variant 
ETV4 bearing point mutations (e.g., F54A, S429A, and F54A/S429A) that are 
deficient for interaction with MED25 for their abilities to promote transformation or 
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migration of normal prostate cells. The activation domain of ETV1/4/5 subfamily 
members also interacts with other general transcriptional factors24 and 
coactivators25, so it would be important to perform the reciprocal experiments 
testing wild-type MED25 or mutants26 that are deficient for interaction with ETV4 
in these functional assays. MED25 is expressed in normal prostate. Therefore, 
two alternative approaches may provide a better readout than the overexpression 
of this protein. The overexpression of only the ACID domain of MED25 could 
“squelch” the activity of MED25 when ETV4 is also expressed. Wild-type and 
mutant fragments could be compared.  Alternatively, expression of MED25 could 
be reduced by RNAi or mutations that interfere with ETV4 interaction could be 
introduced by CRISPR technology in PC3 cells, a prostate cancer cell line that 
expresses ETV427. If these assays suggest that the MED25-ETV4 interaction is 
important for transformation or migration of prostate cells, these mutant proteins 
could be engineered into previously established mouse models of prostate 
cancer22,28,29 in order to study the importance of this interaction in vivo. 
 Recently, the disparate distribution of transcription factors and Mediator 
complexes at enhancers was described30. Approximately 40% of Mediator 
complexes were concentrated at less than 3% of the enhancers, and these so-
called “super enhancers” regulated highly expressed genes that define the 
cellular identity. In several human cancers, the super enhancers appear to be 
redistributed by oncogenic transcription factors, including ETS factors31,32. 
Therefore, it would be interesting to analyze the distribution of Mediator 
complexes in prostate cells before and after the expression of ETV4 using 
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MED25 as a proxy for Mediator complexes. Chromatin immunoprecipitation 
(ChIP) of MED25 and ETV4, individually, followed by next-generation sequencing 
(ChIP-seq) would allow for the identification of co-occupied genomic targets and 
determination of whether the expression of ETV4 changes the distribution of 
MED25. These regions could then be overlapped with enhancers as defined by 
the presence of the coactivator protein p300 and the histone modifications 
H3K4me1 and K3K27ac30,33. 
 
ETS – Mediator interactions 
We propose two possible models for the ETV4 – MED25 interaction 
perturbing Mediator complexes in prostate cells. In the first model, ETV4, through 
interaction with MED25, perturbs the distribution of Mediator complexes and 
recruits Mediator to new genomic loci in prostate cells. In the second model, the 
interaction of ETV4 with Mediator through MED25 results in a conformational 
change that activates the Mediator complex by influencing the recruitment of 
RNA polymerase II and other cofactors. These models are not necessarily 
mutually exclusive, but we will refer to them as the distribution model and the 
activation model, respectively.  
ETV1/4/5 factors interacting with MED25 add to the short list of 
characterized ETS - Mediator subunit interactions; ELK1, ELK3, ELK4, and ELF3 
interact with MED2334-36. As these ETS factors are expressed in the normal 
prostate, their interaction with MED23 may help define the distribution of 
Mediator complexes in the normal prostate. Interestingly, ELF3 belongs to the 
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same ETS subgroup as EHF, a tumor suppressor in the prostate37. Gene 
disruption of MED23 and MED25 results in distinct defects in smooth muscle cell 
differentiation38 and chondrocyte differentiation39, respectively, suggesting that 
these subunits are required for the transcription of a distinct subset of genes. 
Establishing the genes that ELK1, ELK3, ELK4, or ELF3 co-regulate with MED23 
in normal prostate cells would allow us to determine if the overexpression of 
ETV4 alters the transcription of, for example, ELF3-MED23 co-regulated genes. 
The aforementioned distribution model would predict that the overexpression of 
ETV4 would repress the transcription of ELF3-MED23 co-occupied genes by 
recruiting Mediator complex away from these loci. ChIP-seq experiments, as 
described above, for ELF3 and MED23 to determine co-occupied regions would 
be performed before and after ETV4 overexpression in prostate cells. Similar 
occupancy of MED23 at ELF3-MED23 co-occupied sites before and after ETV4 
overexpression would disfavor the distribution model whereas loss of MED23 at 
these sites would favor the distribution model. 
 Interaction with ADs from distinct transcription factors imparts different 
conformational rearrangements of Mediator40-42 and the recruitment of distinct 
cofactors to the Mediator complex43. Therefore, ETV4-MED25 interaction may 
modulate Mediator activity in a manner that is distinct from ELF3-MED23 
interactions. Hybrid ETV4 – ELF3 constructs could be used to test this possibility. 
For example, the AD of ETV4 could be swapped into ELF3. Then the 
transcriptional output from ELF3-MED23 co-regulated genes could be compared 
to wild type ELF3. Similar levels of transcriptional output would favor a pure 
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distribution model, whereas activation of transcription with the ELF3-ETV4(AD) 
hybrid would support differential activation of Mediator from these transcription 
factors. As we determined that the inhibitory α-helix flanking the ETS domain of 
ETV4 also contributes to the binding of MED25, the contribution of the DBDs of 
these factors would need to be considered in these hybrid experiments.  
One potential complication of this line of investigation is the capability of 
many transcription factor ADs to interact with multiple subunits of the Mediator 
complex44-47. This appears to be the case for the ADs of ELK1, ELK3, and ELK4 
as each of these factors has a distinct dependence on MED23 for transcriptional 
activity35 and are capable of associating with the Mediator complex in the 
absence of MED2348. Determining all of the Mediator subunit targets of ETS 
factors in normal prostate and prostate cancer would be necessary in defining 
the differential recruitment of Mediator complexes by these factors. For example, 
as a first pass, a pull-down or an immunoprecipitation with ETV4 followed by 
western blot analysis of individual Mediator subunits would be performed in cells 
expressing MED25, or with MED25 knocked out. If the results indicate that ETV4 
is still capable of interacting with Mediator complexes then mass spectrometry 
analysis of these MED25-null complexes could be utilized to identify putative 
ETV4-targets amongst other Mediator subunits43,49. Nuclear extract from cells 
without MED25 and without the individual putative Mediator subunits could then 
be used to reanalyze ETV4 binding to modified Mediator complexes. Parallel 
experiments would be performed with the other ETS factors of interest.  
 
	   174	  
Inhibition of specific AD interactions with small peptides  
The activation domain of ETV1/4/5 is disordered in isolation, but forms an 
amphipathic α-helix when interacting with transcriptional coactivators. The bulky 
hydrophobic groups of these ADs are functionally important for coactivator 
interactions. This structural character is representative of many transcription 
factor ADs50. The dogma for this structural character is that the disordered, 
flexible nature of ADs allow for interaction with multiple distinct protein 
surfaces51,52. If this dogma were valid, then we would hypothesize that reinforcing 
the bound state of an AD with any single cofactor would inhibit the transcriptional 
activity of that transcription factor. Currently, the absence of solved structures for 
the AD of ETV1/4/5 factors bound to transcriptional cofactors limits the use of 
these proteins for this approach. In contrast, the AD of p53 is an ideal model 
system to test this hypothesis due to the wealth of solved structures with 
numerous cofactors53-57 and the documented biological effects of mutations 
within the AD58. In addition to furthering our understanding of the chameleon-like 
nature of transcription factor ADs, these studies would also provide the basis to 
generate protein domains that specifically inhibit individual AD-cofactor 
interactions.   
Multiple structural conformations in the interaction with distinct 
coactivators has been established for the AD of p5353-57.   Intriguingly, the 
mutation of distinct hydrophobic amino acids within the AD of p53 selectively 
ablates transcription of p53 target genes. The L25Q/W26S double mutant ablates 
the transcription of genes that are important for the response to DNA damage 
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and the W53S/F54Q double mutant ablates the transcription of genes that 
mediate tumor suppression58. The simplest model to describe this distinction is 
that p53 interacts with different coactivators at the genes that control these two 
different cellular functions. The wealth of p53 AD – coactivator structures that 
exist allows for “domain grafting”, a computational approach that incorporates 
amino acids that are known hot-spots for an interaction into a new protein 
domain that favors interaction with the specific coactivator of interest59,60. For 
instance, protein domains could be grafted on to W53 and F54, two hot-spot 
residues for the interaction of the p53 AD with the nuclear receptor coactivator 
binding domain (NCBD) of the CREB-binding protein (CBP)61(Fig. 6.2). 
Alternatively, other structures that interact with this same region of p53 AD, such 
as the RPA70 subunit of replication protein A54, the A box of high-mobility group 
B155, or the pleckstrin homology domain from the TFIIH subunit p6256,62 could be 
used as the starting model. Suitable grafted domains could be further optimized 
with phage or yeast surface display, as described above (Fig. 6.1c), and 
checked for affinity against other p53 coactivators. The resulting protein domains 
from this particular strategy would be predicted to specifically disrupt the 
transcription of p53 target genes that are important for tumor suppression58. 
However, these domains would serve as tools to probe the requirement of 
specific cofactors at p53-regulated genes. Additionally, this general strategy 
could be used to develop de novo protein domains that inhibit p53 gain of 
function mutants that drive cancer development63.   
The structural partnerships and biological knowledge of ETV1/4/5 
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activation domains are currently underdeveloped to take the same exact 
approach, although the maturation of the AD or of H4, the inhibitory α-helix, using 
phage or yeast surface display (Fig. 6.1c) could be utilized to generate higher-
affinity binders for MED25. In order to utilize the approach outlined above, 
structures of ETV4 bound to cofactors, such as MED25, would need to be 
determined.  
 
RAS-MAPK signaling and ETS factors 
We have described an interesting distinction between ETS factors in their 
differential affinity for nonoptimal ETS motifs that occur within ETS-AP1 sites and 
in their differential ability to bind with JUN-FOS at these composite sites. These 
differences lead us to a model where EHF/SPDEF – type ETS factors bind to 
ETS-AP1 composite sites by themselves, and ERG/ETV4 – type ETS factors 
bind to ETS-AP1 composite sites with JUN-FOS. This model is consistent with 
previous descriptions of EHF and SPDEF as transcriptional repressors and ERG, 
ETV1, and ETV4 as transcriptional activators of ETS-AP1 composite sites14,15. 
Next, we will test whether this model aptly describes ETS-AP1 partnerships in 
cells.  
First, we will explore the preferences of ETS factor binding with JUN-FOS 
by genomic occupancy experiments. Genome-wide analyses of ERG, ETV1, and 
ETV4 following the overexpression of these factors in normal prostate cells have 
been performed, and these factors occupy regions of the genome that are 
enriched with ETS-AP1 composite sites14. EHF and SPDEF binding to select 
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ETS-AP1 composite sites in normal prostate cells has been described, but not 
defined in a genome-wide manner14,15. ChIP-seq experiments for EHF/SPDEF in 
normal prostate cells would first describe the prevalence of EHF/SPDEF binding 
to ETS-AP1 composite sites in the normal prostate. Next, overexpression of ERG 
in conjunction with ChIP experiments for JUN or FOS would determine whether 
the occupancy of JUN-FOS is affected by specific ETS factors, as predicted by 
our in vitro experiments.  
Next, we will test whether the DNA-binding intrinsic to the ETS domain, 
the antagonism of JUN-FOS binding nearby, or both features, are important for 
EHF and ERG in cells. The differential binding to nonoptimal ETS DNA sites and 
the differential binding with JUN-FOS appear to be separate features of ERG and 
EHF: the difference in DNA affinity resides within the ETS domain of both factors; 
whereas, the antagonism of JUN-FOS binding occurs outside of the ETS domain 
of EHF. We could design mutations that will interconvert each, or both, of these 
differential properties between ERG and EHF, then test in the genomic 
occupancy experiments.  
In the future, we would plan to move closer to studying expression of ETS-
AP1 regulated genes, either by surveying changes in RNA expression of genes 
associated with genomic-occupancy or by use of cell migration as a proxy.  
 
Development of assays to screen for inhibitors of ETS partnerships 
Transcription factors remain difficult drug targets. Small ideal drug-like 
molecules are a fraction of the size of the large and broad surfaces that are 
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typical of transcription factor – DNA interactions64. Further understanding of the 
mechanisms through which transcription factors operate provides alternative 
target sites for the therapeutic disruption of transcription factor function. If either 
the ETV4 - MED25 interaction or the ERG - JUN-FOS partnership appears to be 
functionally important for prostate cancer, as determined by the experiments 
described above, this would motivate the development of inhibitors of these 
partnerships. The assays described in Chapter 2 could be modified to 
incorporate either of these components (Fig. 6.3). For example, ETV4 would be 
added to fluorescein-tagged DNA to increase the fluorescence polarization of the 
DNA. MED25 would interact with ETV4 and further increase the size of the DNA-
bound complex and therefore the fluorescence polarization signal. Efficient 
inhibitors of the ETV4 - MED25 interaction would reduce the fluorescence 
polarization signal back to level of the ETV4 – DNA complex. A conceptually 
similar assay could be designed for ERG and JUN-FOS binding to an ETS-AP1 
composite DNA site. These modified assays could then be used to perform high-
throughput screens for inhibitors of these interactions.    
 
Finale 
The development of small molecule inhibitors for transcription factors 
against the macromolecular contacts that these proteins form is a daunting 
challenge. However, the disease relevance of ETS factors, as well as many other 
transcription factors, necessitates the development of novel strategies for the 
therapeutic perturbation of these proteins’ functions65,66. Here, I have described 
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the DNA-binding autoinhibition of ETV4 and its interaction with MED25, both 
features that appear to be unique to the ETV1/4/5 subclass of ETS factors. 
Additionally, I have demonstrated distinct partnerships with JUN-FOS 
transcription factors between different subclasses of ETS factors. I propose that 
these findings provide a framework for novel routes to specifically perturb the 
transcriptional activity of individual subclasses of ETS factors.
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Figure 6.1. Further investigation of the ETV4 N-terminal inhibitory domain (NID). 
(a) Model for NID-mediated autoinhibition. Two separate regions of the NID (cyan 
ovals) inhibit DNA-binding by the ETS domain. Acetylation of lysine residues 
within these regions disrupts autoinhibition. (b) To facilitate further analysis of 
autoinhibition within the NID, I propose attaching single or multiple copies of the 
conserved region surrounding lysine 226. I would expect that the more copies 
that are present, the higher the level of DNA-binding inhibition would be (right). 
This more robust level of autoinhibition would enable easier dissection of the 
inhibitory region through point mutagenesis. (c) Definition of the minimal 
inhibitory unit would allow for affinity maturation of the interaction between this 
inhibitory unit and the ETS domain of ETV4. (1,2) The conserved region 
surrounding lysine 226 would be randomly mutagenized. In this case, I designed 
an experimental setup that would conserve the flanking sequences (ΦKXE) that 
allow for dual acetylation and sumolyation of lysine 226. (3) Interaction with the 
ETS domain of ETV4 would be used to select inhibitory sequences with higher 
affinity from the mutagenized library. (4) Subsequent rounds of mutagenesis are 
used while fixing residues that favor ETV4 interaction. A control ETS domain, 
from EHF for example, could be used to select for specificity as well as affinity. 









Figure 6.2. Domain grafting as a method for increasing the specificity of an 
activation domain for a particular coactivator target. Left, the structure of the 
activation domain of p53 (magenta) bound to the NCBD domain of CBP (gray)53 
(2L14.pdb). W53 and F54 of the p53 AD are labeled and shown in stick format. 
These residues are critical for interaction with CBP NCBD. Right, after optimizing 
the orientation of the side chains of W53 and F54 for interaction with CBP NCBD, 
the incorporation of these amino acids into a library of protein domains (magenta 
polygons) is performed in silico to predict which domain(s) would favor interaction 
with CBP NCBD, in a process termed domain grafting. The resulting domain 
grafts could be analyzed for specific interaction with CBP NCBD, compared to 
other targets of p53 AD, and further optimized using the affinity maturation 
process described that was previously described (Fig. 6.1c).     









Figure 6.3 Hypothetical assay to screen for inhibitors of ETV4 – MED25 
interaction. (a) Schematic of fluorescence polarization assay with fluorescein-
labeled DNA, ETV4, and MED25. (b) Predicted results for an inhibitor of ETV4-
MED25 interaction. Addition of ETV4 increases the fluorescence polarization of 
the DNA (ETV4-DNA), and interaction between MED25 and ETV4 further 
increases the fluorescence polarization of the DNA (MED25-ETV4-DNA). 
Efficient inhibition of the MED25-ETV4 interaction would return the fluorescence 
polarization signal to near ETV4-DNA levels.  
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